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Saccular intracranial artery aneurysm (IA) rupture causes subarachnoid hemorrhage
(SAH), with up to 50% mortality. Of the population, 2.3% is estimated to harbor
unruptured aneurysms. To date, rupture risk of an individual IA cannot be precisely
predicted. Especially young patients with unruptured IAs with risk factors, such as
smoking, hypertension, and family history, need active treatment to prevent the often fatal
IA rupture. Current treatment options (endovascular or microsurgical therapy) are invasive
and associated with some morbidity and mortality. Rupture-prone IAs should be identified
and this requires a better understanding of the IA wall pathobiology. Inflammatory cell
infiltration and IA wall degeneration are known to precede IA rupture. The complement
system is a key mediator of inflammation and house-hold processing of injured tissue. The
role of complement activation in IA wall pathobiology is unknown. This study aimed at
identifying the role of complement activation in IA wall degeneration and the complement
activators involved and determining how the complement system is regulated in the IA
wall.
Materials and methods
The presence of complement activation, complement activators, and complement
regulators was evaluated by immunostainings of samples of unruptured and ruptured IA
fundi, resected perioperatively after microsurgical clipping. The relative localization of
complement activation within the IA wall and in relation to complement activators and
regulators was analyzed in IAs by light and fluorescence microscopy from single and
double stainings. The extent of complement activation was correlated with clinical and
histological parameters. The localization of the terminal complement complex at the
ultrastructural level and its relation to cell death were analyzed by electron and
immunoelectron microscopy. As complement activation may induce cellular death, a
special emphasis was placed on assessing the potential role of complement activation in
cell loss in the IA wall. The disease-associated Y402H polymorphism in complement
inhibitor factor H was also investigated.
Results
The end-product of complement activation, the terminal complement complex (TCC), was
located mainly in the outer part of the IA wall, in areas that had also sustained loss of
cells. Complement activation correlated with IA wall degeneration and rupture, de-
endothelialization, and T-cell and CD163-positive macrophage infiltrations. The area of
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maximum TCC accumulation contained cellular debris and evidence of both apoptotic and
necrotic cell death. The complement system was found to become activated by the
classical pathway, with recruitment of alternative pathway amplification. This suggests the
presence of chronic inflammation and complement activation in response to specific
activators. Complement activation elicited by more than one specific activator was also
suggested by the probable complement activators being scattered within IA walls,
similarly to the early components of complement activation. Lipid accumulation was
observed to clearly colocalize with C5b-9 and C-reactive protein. Lipid deposits thus
likely have a role in complement activation and/or indicate impaired clearance
mechanisms. Terminal pathway complement activation was limited to the outer part of the
IA wall. In other areas, complement activation was limited by cellular expression of
protectin (CD59) and extracellular matrix-bound inhibitors, C4b binding protein and
factor H. The outer part of the wall was exposed to terminal complement activation due to
a lack of cells expressing protectin as well as matrix-bound factor H. Unlike in age-related
macular degeneration, factor H Y402H polymorphism was not associated with the
presence of IAs or their rupture.
Conclusions
The data suggest that complement activation and TCC formation are involved in IA wall
degeneration and rupture. The association of complement with de-endothelialization and
expression of complement activators indicate a possible role of endothelial dysfunction in
the pathobiological process. Furthermore, impaired clearance mechanisms may be
involved in chronic inflammation. Whether complement activation is primary or
secondary to cell death could not be determined. Impaired complement regulation seems
to be associated with increased complement activation in IA walls. These results stress the
role of chronic inflammation in IA wall pathobiology and the regulatory role of
complement within this process. The IA wall is exposed to mechanical hemodynamic
stresses, humoral inflammation, and innate immune attack. Complement deposits might
thus serve as a marker of long-term stress in the IA wall, an attempt to remove debris, or
disturbed complement regulation in the matrix. Whether inherent disturbances in function
or regulation of the complement system exist should be examined in future studies.
Imaging inflammation would enhance the diagnostics of rupture-prone IAs, and targeting




Subarachnoid hemorrhage (SAH, Figure 1A), caused by a rupture of an intracranial artery
aneurysm (IA), has been recognized as a disease entity already for thousands of years
(Clarke, 1963). Today, SAH of aneurysmal origin accounts for 1-7% of all strokes in
Western countries (Feigin et al., 2003).
Intracranial artery aneurysm is a protrusion of a cerebral artery in the vicinity of
the circle of Willis (Figure 1B), which is an arterial circle providing blood supply to the
brain at the skull base. IAs are classified as saccular (or berry) or fusiform according to
shape and relation to the conducting artery (Figure 1C). This study deals with saccular IAs
only. IAs are usually located at the branching points of intracranial arteries, the most
typical bifurcations being at the anterior communicating artery (AComA), posterior
communicating artery (PComA), and middle cerebral artery (MCA).
IAs are usually symptomless until they rupture, with the exception of giant IAs,
which may cause neurological symptoms by mass effect. When an IA ruptures, arterial
blood bleeds into the subarachnoidal space, causing sudden headache, nausea, vomiting,
and possibly neurological deficit. Sometimes IAs also bleed into the brain parenchyma,
leading to intracerebral hemorrhage (ICH, Figure 1A).
Figure 1. Subarachnoid hemorrhage (A), circle of Willis (B), and intracranial artery
aneurysms (C). In subarachnoid hemorrhage, blood is seen in the subarachnoid space (arrow)
around the brain in a computer tomography image, in this case with an associated intracerebral
hematoma (asterisk, A). A magnetic resonance angiography image of the circle of Willis, an
arterial ring located at the skull base (B). Computer tomography angiography images of a typical
saccular aneurysm pouching at the arterial bifurcation and a fusiform aneurysm appearing as a
dilatation of a cerebral artery (C). The images are from different patients.
There are several risk factors for IA growth and rupture, but the primary etiology
remains unknown. IAs are considered acquired and not congenital lesions (Stehbens,
I Introduction
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1989), and arise de novo (Graf and Hamby, 1964). Rarely, IAs may be associated with
vascular anatomic variations, infections, traumas, neoplasms, systemic disorders, or drug
abuse (reviewed by Biondi, 2006). Recent studies have strengthened the concept that a
chronic inflammation predetermines IA wall degeneration towards a rupture-prone
phenotype.
Inflammation is a normal tissue’s reaction to physical, chemical, or biological
stress or injury. It manifests as an immunological response and accumulation of
inflammatory cells. Inflammation was first suggested to occur in IAs by Virchow
(Virchow, 1847; Chyatte et al., 1999). Further evidence comes from the 1930s, when
Maass (Maass, 1937; Hassler, 1961) described a round-cell infiltration, most likely
lymphocytic, especially in the IA neck. Later, after the introduction of modern molecular
biological and immunostaining methods, several studies have shown the presence of
inflammatory cell infiltration and inflammatory mediators in the IA wall, and their
association with critical weakening and rupture of the IA wall. A well-known, but
extremely rare cause of IAs and their rupture is a local bacterial infection associated with
an inflammatory response triggered by the pathogen. This underlines the capability of
local inflammation to destroy tissue.
The complement system can launch inflammatory reactions by approximately 35
components. It is a major part of innate immunity, which also regulates the adaptive
immune system. Growing evidence points to an important role of the complement system
in response to injury, involving the clearance of tissues from accumulating debris together
with phagocytes. In general, components of the complement system can recognize foreign
particles and alterations in host cell surfaces and structures. Many noninfectious factors
are capable of activating complement, including antibodies, C-reactive protein (CRP),
oxidatively modified lipids and proteins, and membrane phospholipids of apoptotic or
necrotic cells. If complement activation is not inhibited by membrane-bound or soluble
complement inhibitors, it ultimately leads to the formation of the membrane attack
complex (MAC), which can cause death of a target cell (Sim and Tsiftsoglou, 2004; Biró
et al., 2007; Sjöberg et al., 2009). The small fragments, anaphylatoxins, that are generated
during complement activation are chemotactic to inflammatory cells and have many
effects on the functions of inflammatory cells and the vascular wall (Klos et al., 2009).
Although the presence of two complement components in the IA wall has been
shown previously (Chyatte et al., 1999), the characteristics and consequences of
complement activation in the IA wall are still unknown. As molecular imaging and
targeted pharmaceutical therapy continue to develop at an accelerating pace, defining the
mechanisms of IA wall degeneration and rupture is increasingly important. This study
adds to the knowledge of complement activation in IAs, based mostly on
immunohistochemical studies. It describes the regulatory mechanisms of complement, as
I Introduction
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well as the relation of complement activators to actual complement activation in IA walls.
The association and potential mechanisms of complement activation and IA wall
degeneration and rupture are also discussed.
II Review of the literature
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II REVIEW OF THE LITERATURE
1 Intracranial artery aneurysm and subarachnoid
hemorrhage
1.1 Epidemology
Of the population, 2.3% (0.4-6.0%) has been estimated to carry IAs, based on a series of
radiological imaging and pathological examinations (Rinkel et al., 1998). Eighty-five
percent of SAHs are of aneurysmal origin (aneurysmal SAH; aSAH) (van Gijn et al.,
2007). In a meta-analysis, the incidence of SAH was 9.1 per 100 000 person-years in
Europe and North America, halved in South and Central America (4.2 per 100 000) (de
Rooij et al., 2007), and twice as high in Finland (19.7 per 100 000) and Japan (22.7 per
100 000) (Linn et al., 1996; Morita et al., 2005; de Rooij et al., 2007). The reason for a
higher prevalence of SAH in Finland and Japan is unknown.
The reported annual rupture rate of IAs varies between 0.05% and 2.3%,
depending on the inclusion criteria. It is higher in patients with previous SAH and larger
IAs (Yasui et al., 1997; ISUIA, 1998; Juvela et al., 2000; Suga et al., 2002; Wiebers et al.,
2003; Ishibashi et al., 2009), as confirmed by the meta-analysis of Rinkel et al. (1998).
Patients with familial background (Broderick et al., 2009) or prior SAH and multiple IAs
(Heiskanen, 1981; Winn et al., 1983) have an annual rupture rate of 1-1.2%.
1.2 Risk factors for intracranial aneurysm rupture
The general risk factors for IA rupture are hypertension, smoking, female gender, alcohol
and drug abuse, and family history. The size and location of the aneurysm as well as the
genetic background of the patient and age affect the risk of rupture. As most SAHs are
aneurysmal in origin (van Gijn et al., 2007), it is also relevant to review here the risk
factors for SAH in general.
1.2.1 Aneurysm-related risk factors
Location
IAs in posterior circulation have a higher rupture risk than those in anterior or medial
circulation (Rinkel et al., 1998; Wiebers et al., 2003; Clarke et al., 2005; Morita et al.,
2005; Ishibashi et al., 2009). However, relative to other locations, anterior circulation IAs
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tend to rupture when they are smaller (Orz et al., 1997; Ohashi et al., 2004; Beck et al.,
2006). In patients with multiple IAs, the proximal one has ruptured in 60-70% of cases
(Jain, 1963; Crompton, 1966).
Size
Several studies and meta-analyses have reported a correlation between IA size and rupture
rate (Rinkel et al., 1998; Wiebers et al., 2003; Morita et al., 2005; San Millan Ruiz et al.,
2006; Ishibashi et al., 2009). Size has been evaluated as an independent predictor for an
IA rupture (relative risk 1.11 per mm) (Juvela et al., 2000). However, small IAs are also at
risk for rupture (Crompton, 1966; Orz et al., 1997; Ohashi et al., 2004; Beck et al., 2006).
In patients with multiple IAs, the largest IA has ruptured first in most cases (74-88%)
(Wood, 1964; Crompton, 1966; Orz et al., 1997).
Growth, morphology, and multiplicity
The growth of ruptured IAs is more marked than that of unruptured IAs (Björkesten and
Troupp, 1962; Matsubara et al., 2004). Secondary pouches and nonspherical shape, related
to IA growth, are associated with a higher tendency for IA rupture (Crompton, 1966; San
Millan Ruiz et al., 2006; de Rooij et al., 2009). Sometimes IAs grow to a size of several
centimeters; these are referred to as giant aneurysms (Barth and de Tribolet, 1994).
Multiple IAs are present in up to 34% of patients with diagnosed IAs (Ostergaard and
Hog, 1985; Rinne et al., 1994; Inagawa, 2009). Multiple IAs may rupture more easily, as
the history of SAH (majority of multiple IAs) is a significant risk factor for IA rupture
(Ishibashi et al., 2009).
1.2.2 Patient-related risk factors
Age
The average age of an aSAH patient is 57 years (ACROSS, 2000). The prevalence of IAs
is very low in the first two decades of life, but increases steadily after the third decade
(Rinkel et al., 1998). As the patient gets older, the IA rupture risk increases as the annual
rupture risk accumulates (Juvela et al., 2000). Patients with a family history have IA
ruptures at a younger age (Ohashi et al., 2004).
Female gender
IAs become more common in females with age (Kongable et al., 1996; de Rooij et al.,
2007), and women have a higher risk for IA rupture in general (Rinkel et al., 1998; Morita
et al., 2005). Female gender is also an independent risk factor for de novo IA formation,
IA growth (Juvela et al., 2001), and multiple aneurysms (Ostergaard and Hog, 1985;
II Review of the literature
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Kongable et al., 1996; Inagawa, 2009). The risk for SAH increases after menopause
(Stober et al., 1985; Longstreth et al., 1994), but can be reduced by hormone replacement
therapy (Longstreth et al., 1994; Mhurchu et al., 2001). This might be mediated by
estrogen effects on the vascular wall (Harrod et al., 2006).
1.2.3 Environmental factors
Smoking and alcohol abuse
Smoking has been considered the strongest risk factor for SAH (Feigin et al., 2005a), with
a relative risk of 2.2-3.1 (Feigin et al., 2005b), and is related to IA size (Qureshi et al.,
2000) and rupture (Juvela et al., 2000). Excessive alcohol use correlates with IA rupture
(de la Monte et al., 1985), with a relative risk of 2.2 (Feigin et al., 2005b). Reports also
indicate increased risk of SAH with recent use of cocaine (Broderick et al., 2003) or
caffeine (Isaksen et al., 2002; Broderick et al., 2003).
Hypertension
Patients with an aSAH have been found to be hypertensive almost twice as often as
nonaneurysmal SAH patients (Stober et al., 1985; Inci and Spetzler, 2000), and
hypertension increases the risk for SAH (Feigin et al., 2005a) and small-sized IA ruptures
(Ohashi et al., 2004). Hypertension is also the most important risk factor for multiple IAs
(Ostergaard and Hog, 1985).
1.2.4 Family history
Approximately 10% of SAH patients have a family history of IAs (Ruigrok et al., 2001).
The prevalence of carrying IA, as a member of a family with two or more affected
members, increases to 8.7% (Ronkainen et al., 1997), and in the presence of acquired risk
factors, the risk increases further to 32% (Nakagawa et al., 1999). However, first-degree
relatives have only a slightly increased incidence (4%) (Raaymakers, 1999; Wang et al.,
2002). IA patients with a family history are more often women (80%) (Leblanc, 1996), the
patients are slightly younger (by 2-4 years), and the aneurysms are smaller and more often
multiple than in patients with sporadic IAs (Ronkainen et al., 1995).
1.3 Diagnosis, prevention of rupture, and treatment
IA rupture causes sudden onset of headache with vomiting, neck stiffness, often short loss
of consciousness, and/or focal neurological symptoms, especially in the case of an
intracerebral hemorrhage. SAH is diagnosed by computer tomography (CT), magnetic
resonance imaging (MRI), or lumbal puncture. IA is finally identified in CT, MR, or
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catheter angiography (van Gijn et al., 2007). Nowadays, a growing number of IAs in
clinical practice are unruptured, incidental findings in patients imaged primarily for
reasons other than IAs or to screen families with IAs. The risks of active treatment must
then be weighed against the natural course of the disease in individual patients and the
probable risk of lifetime rupture estimated.
IAs are treated to prevent rupture or re-rupture. An IA that has ruptured once has
an increased risk of up to 39% to re-bleed without an intervention (Winn et al., 1983;
Hijdra et al., 1987; Ohkuma et al., 2001; Brilstra et al., 2002). The current options to
prevent rupture or re-rupture of an IA are clipping and endovascular embolization
(endovascular therapy, EVT), both invasive and somewhat risky (King et al., 1994;
Raaymakers et al., 1998; Molyneux et al., 2002; Lanterna et al., 2004; Fraser et al., 2006).
1.4 Outcome
Approximately half of the patients with SAH die and half of those surviving have
hindered daily living (van Gijn et al., 2007). The fatality rate of SAH in the 1960s to the
1990s was as high as 67-32%, showing a decreasing profile with an annual minimum
decrease of 0.5% in the case fatality rate (Hop et al., 1997; Nieuwkamp et al., 2009).
Patients surviving from SAH have been reported to suffer from altered personality,
memory problems, daytime sleepiness, problems sleeping at night, reduced ability to
work, and headaches (Ogden et al., 1997; van Gijn et al., 2007). Epilepsy develops in 5-
7% of patients (Claassen et al., 2003; Buczacki et al., 2004). A factor affecting the
outcome is delayed vasospasm, which develops in up to half of the patients, leaving 30%
of these patients with permanent neurological deficit (Dorsch and King, 1994; Pluta et al.,
2009).
1.5 Histopathology of intracranial aneurysms
The primary reasons for IA formation and rupture remain obscure. As the rates of IA
rupture and incidental unruptured IAs increase with age, and IAs have been found to arise
de novo (Graf and Hamby, 1964), IAs are thought to be acquired rather than congenital
lesions (Stehbens, 1989). IA wall histology reveals a vascular wall that varies in histology.
At gene-expression level, the most impacted functional pathways in IAs, in comparison
with extracranial arteries, are pathways involved in focal adhesion, extracellular matrix
receptor interaction, cell communication, inflammatory response, and apoptosis (Shi et al.,
2009).
II Review of the literature
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1.5.1 Cerebral artery wall
Cerebral arteries, like extracranial arteries, normally comprise three histologically
different layers: the intima consisting of endothelial cells, the media rich in smooth muscle
cells (SMCs), and the adventitia with fibroblasts as the main cellular component. The
intima and media are separated by a well-preserved, homogeneous, but fenestrated internal
elastic lamina (IEL) (Nyström, 1963). As an age-related change, IEL may reduplicate
(Hassler, 1961). The media consists of regular layers of SMCs surrounded by collagenous
bundles and sparse elastic fibers (Nyström, 1963). Distinct from extracranial arteries,
cerebral arteries lack the fully developed external elastic lamina that otherwise separates
the media and the adventitia. The adventitia of cerebral arteries is only weakly developed
(Nyström, 1963) (Figure 2A).
Cerebral arteries rarely have vasa vasori. Vasa vasorum-like vessels have been
found only in the proximal segments of the internal carotid and of the vertebral arteries
with a thickness of more than 250 m (Aydin, 1998). Small vascular channels have also
been described in the outer media and adventitia of more proximal segments of anterior
and medial cerebral arteries (A1 and M1) (Connolly et al., 1996). They are seen more
often in cerebral arteries with atherosclerosis (Atkinson et al., 1991; Aydin, 1998) or
thrombosis (Aydin, 1998). Vasoconstriction and vasodilatation of intracranial arteries are
partly controlled by the perivascular fiber system of the autonomous nervous system, seen
as longitudinal bundles in the periadventitia-adventitia and as a network-like reticular
structure at the adventitia-media border (Buki et al., 1999).
1.5.2 Intracranial aneurysm formation
Typical saccular IAs form at the bifurcation of cerebral arteries. Contrary to the normal
cerebral artery structures (i.e. intima, IEL, media, and adventitia), the apical part of the
cerebral artery bifurcation lacks the medial layer of SMCs (Hassler, 1961) (Figure 2B).
The gap in the medial layer is called a ‘medial raphe’ (Stehbens, 1999a), and the media is
replaced by tendon-like, linearly organized collagen (Finlay et al., 1998). A role for the
medial raphe in IA formation is unlikely, but still being explored (Stehbens, 1999a)
(Figure 2C).
IEL disruption and an associated vascular wall remodeling have been thought to
precede IA formation. Tears in IEL have been detected at cerebral artery bifurcations of
normal cerebral arteries, and at even a higher incidence in IA patients (Hassler, 1961). The
site of the tear in IEL is often associated with a pad of myointimal hyperplasia in the
intima (Stehbens, 1960; Hassler, 1961). Half of the degenerative changes of IEL and
media are located at some distance from the apex (Kayembe et al., 1987). In experimental
models of aneurysms, the hemodynamics only causes transversely oriented tears and
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fragmentation of IEL (Stehbens, 1999b). Experimental studies have shown that the
primary aneurysmal changes did not develop at the apical tip, but a small distance away,
next to the intimal pad (Jamous et al., 2007; Wang et al., 2009) (Figure 2C). However,
during IA growth, also the bifurcation becomes involved, manifesting typical macroscopic
feature of an IA.
Figure 2. Histological structures of a normal cerebral artery wall (A) and an intracranial
aneurysm wall (B), and a schematic presentation of aneurysm formation (C). The normal
cerebral artery wall has endothelium, internal elastic lamina (IEL), a medial layer of linearly
organized smooth muscle cells, and adventitia, whereas the wall of an intracranial aneurysm lacks
IEL and often also endothelium, and shows varying amounts of myointimal hyperplasia. The
aneurysmal nidus, typically located a small distance from the arterial bifurcation (open arrow),
reaches the bifurcation by growth so that the ‘medial raphe’ (arrowhead) soon becomes a part of
the IA.
IA patients may have either a hereditary or acquired predisposition for structural
disturbances in their cerebral arteries. IA patients, contrary to healthy individuals, have a
significantly higher incidence of small evaginations, thinnings of the media, and
dilatations at the apical area in their cerebral artery bifurcations (Kayembe et al., 1987). In
the cerebral arteries of IA patients, the amount of reticular fibers is reduced by up to 35%
(Ostergaard et al., 1987b), predominantly in the outer part of the media (Hegedus, 1984).
In normal cerebral arteries, fine reticular fibers form a dense network that surrounds the
SMCs of the media and is present independently of intimal proliferation with age.
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Moreover, the content of hyaluronan, an extracellular matrix (ECM) component that
probably contributes to the viscoelastic resistance of cerebral arteries, is increased in
cerebral arteries of IA patients compared with normal controls (Klekner et al., 2005).
1.5.3 Intracranial aneurysm wall
The IA wall often shows a gradual change from almost intact to highly degenerated wall
in the neck to fundus direction (Frösen et al., 2004; Rajesh et al., 2004). Degenerative
changes in the IA wall include a decrease in the number of mural cells, mainly SMCs, an
excess in the amount of fibrous tissue, and, ultimately, thinning of the wall. However, the
IA wall is also under a constant remodeling process, indicated by disorganization of the
wall structures, myointimal hyperplasia, and SMC proliferation.
IA wall is characterized by loss of IEL, which normally gives mechanical strength
to the cerebral artery wall. The IEL typically ends at the level of the IA neck, where the
IEL divides into branches ending in connective tissue (Hassler, 1961; Scanarini et al.,
1978a), leaving only remnants, if any, in the aneurysmal wall (Nyström, 1963; Scanarini
et al., 1978a; Frösen et al., 2004). The endothelium in IAs often shows various degrees of
damage (Kataoka et al., 1999; Frösen et al., 2004). In electron microscopy, the normally
smooth and linearly organized endothelium has an irregular surface and intracytoplasmic,
probably lipidic, vacuoles (Scanarini et al., 1978a). The medial layer is disorganized
(Frösen et al., 2004; Rajesh et al., 2004), often with scarce SMCs within the fibrohyaline
tissue rich in collagen (Scanarini et al., 1978a; Sakaki et al., 1997). In histology, the
fibrohyaline tissue appears eosinophilic and might occur together with inflammatory cells
(Hassler, 1961). SMCs have undergone at least a partial phenotypic change from
contractile towards synthetic type (Nakajima et al., 2000). In electron microscopy, the
SMCs are stretched, elongated, irregularly arranged, and separated by thick connective
tissue processes (Nyström, 1963). The adventitia of the IA resembles that of a healthy
cerebral artery (Hassler, 1972; Scanarini et al., 1978b) (Figure 2C).
Vasa vasori (Scanarini et al., 1978a; Atkinson et al., 1991), periadventitial vessels
(Holling et al., 2009), and capillaries (Nyström, 1963) can also be found in the wall of an
IA. As a sign of intramural bleedings, the IA walls sometimes contain erythrocytes
(Nyström, 1963; Scanarini et al., 1978a; Kataoka et al., 1999) and hemosiderin (Schlote
and Gaus, 1994; Rajesh et al., 2004; Holling et al., 2009). These indicate earlier, local,
clinically silent bleeding. In IAs, the distribution of the perivascular fiber system,
responsible for vasoconstriction and vasodilatation, does not follow any organized pattern.
Instead, it shows wave and whirl-like patterns and cannot be detected in the circumscribed
areas at all (Buki et al., 1999). Sometimes the IAs have a luminal thrombus, fresh or
organized with thin-walled capillaries, fibroblasts, and minimal amounts of extracellular
mucoid material (Frösen et al., 2004; Rajesh et al., 2004). The IA wall also has signs of
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atheromatous and atherosclerotic changes, cellular death, inflammatory cell infiltrations
(of polymorphonuclear leukocytes (PMNs), macrophages, T-cells, B-cells, and natural
killer cells (NK-cells)), and ECM remodeling, described in detail in the following sections
and summarized in Section 1.5.4.8.
Rupture site
IAs show an uneven distribution of rupture sites; 83-84% rupture at the apex, 13-14% at
the body, and 2% at the neck (Crawford, 1959; Crompton, 1966). The margin of the
rupture site contains fibrin (Crompton, 1966), seen with, but never without, an
(inflammatory) cell infiltration. The inflammatory cells at the site of the IA rupture have
been identified as activated macrophages, T-cells, and NK-cells (Kosierkiewicz et al.,
1994). There is also endothelial damage and partial degeneration at and near the rupture
site (Scanarini et al., 1978a; Kataoka et al., 1999). Apoptotic cell death is more common
near the rupture site than in other parts of the wall (Hara et al., 1998). A fresh,
unorganized, extraluminal thrombus may also be seen at the rupture site (Nomura et al.,
2000).
Differences between unruptured and ruptured aneurysms
Ruptured IAs often show a decreased SMC content in their walls (Sakaki et al., 1997;
Kataoka et al., 1999; Frösen et al., 2004; Kilic et al., 2005). Interestingly, in the study of
Kataoka et al. (1999), the symptomatic but unruptured IAs revealed similar histological
changes as the ruptured IAs. Thus far, only two major studies comparing the histological
parameters of unruptured and ruptured IAs have been performed (Kataoka et al., 1999;
Frösen et al., 2004).
Kataoka investigated a series of 27 unruptured and 44 ruptured IAs, observing that
ruptured IAs had marked endothelial damage. The endothelial cells represented a
disrupted arrangement and shape, with intra-endothelial gaps filled with blood cells. In
some cases, even total destruction of the endothelium was seen. The wall of the ruptured
IAs was also more degenerated with disorganization of type IV collagen, scattered,
diminished, or totally lost SMCs, and even hyalinization. Macrophage and leukocyte
infiltration and expression of the proteolytic enzymes cathepsin D and G were greater in
ruptured IAs. Unruptured IAs, in turn, often showed an almost intact, longitudinally
organized endothelium of the IA wall, dense SMCs, regular layers of type IV collagen,
and only a few macrophages and cathepsin D-positive SMCs in the outer layer of the wall
(Kataoka et al., 1999).
Frösen classified 24 unruptured and 42 ruptured IA walls into types A, B, C, and D
according to their proliferative and degenerative changes. The lowest risk of rupture was
found within normal-looking IA walls (A-type). The rupture risk increased gradually for
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thicker walls with myointimal hyperplasia and an occasional thrombus (B-type), thicker
thrombosed walls with a reduced number of mural cells (C-type), and thin hypocellular
walls with an organized thrombus (D-type). The ruptured IAs showed an increased
proportion of apoptosis, de-endothelialization, organizing luminal thrombosis, SMC
proliferation, and infiltration of macrophages and T-cells (Frösen et al., 2004). An
increased incidence of apoptotic cells (Sakaki et al., 1997; Pentimalli et al., 2004),
inflammatory cells (PMNs and lymphocytes), and partially organized thrombi (Schlote
and Gaus, 1994) have been associated with IA rupture also in other studies.
The pattern of vascular growth factor expression differs between unruptured and
ruptured IAs. Vascular endothelial growth factor (VEGF) is expressed more abundantly in
ruptured than unruptured IAs, especially in the adventitia. In contrast, the basic fibroblast
growth factor (bFGF) is slightly less expressed in ruptured than unruptured IA walls (Kilic
et al., 2005). In a study of 12 different growth factor receptors in 21 unruptured and 35
ruptured IAs, only VEGF receptor 1 and the transforming growth factor beta (TGF- )
receptor type II were found to be associated with IA rupture (Frösen et al., 2006b).
There are also differences in ECM expression and turnover and IA wall
remodeling between unruptured and ruptured IAs. Fibronectin and collagen III are more
densely expressed and type IV collagen expression is decreased in ruptured IAs compared
with unruptured IAs (Kilic et al., 2005). Matrix degradation appears to be increased in
ruptured IAs, as judged by increased expression of matrix-degrading enzymes matrix
metalloproteinase (MMP) -2 and MMP-9 relative to their endogenous inhibitors (tissue
inhibitor of metalloproteinase; TIMP) (Jin et al., 2007). The vasa vasori of ruptured IAs
show sclerotic changes, disturbances of the internal elastic lamina, and partial occlusion of
the lumen by probable thrombotic material (Scanarini et al., 1978a).
1.5.4 Mechanisms altering intracranial aneurysm wall structure
Many of the histological changes seen in the IA wall relative to the normal cerebral artery
wall reflect degenerative and compensatory remodulatory processes. The following
sections discuss the possible roles of these stress-response mechanisms in IA wall
pathobiology.
1.5.4.1 Endothelial dysfunction
De-endothelialization is associated with IA rupture (Kataoka et al., 1999; Frösen et al.,
2004). Endothelial damage has been shown to be one of the first changes in hypertension-
induced experimental IAs in rodents (Jamous et al., 2007). Pressure and shear stress from
circulating blood are necessary for the normal functioning of endothelial cells (Chien,
2008). As the flow alters during IA progression, the hemodynamic impact on the
endothelium changes. This probably sustains molecular signaling of pro-inflammatory and
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proliferative pathways (Chien, 2008). As a probable sign of dysfunction, the endothelial
cells of human IAs express monocyte chemoattractant protein-1 (MCP-1) (Cao et al.,
2002; Krischek et al., 2008; Aoki et al., 2009b) and vascular cell adhesion molecule-1
(VCAM-1) (Chyatte et al., 1999; Shi et al., 2009). MCP-1 is chemotactic to inflammatory
cells, macrophages, T-cells, NK-cells, and basophils, and VCAM-1 aids leukocyte
recruitment. The induction of MCP-1 and VCAM-1 likely occurs through an activation of
transcription factor nuclear factor kappa B (NF B), as seen in the early phase of
experimentally induced IAs in rodents (Aoki et al., 2007c). NF B plays a key role in
regulating immune responses. It is involved in cellular responses to stress, cytokines, free
radicals, and oxidatively modified low density lipoproteins (oxLDL). Strong activation of
NF B has been observed in human IAs, mainly in intimal cells (Aoki et al., 2007c).
1.5.4.2 Inflammatory cell infiltration
Inflammatory cell infiltrations have been detected in unruptured IAs at locations where the
IA wall typically breaks upon an IA rupture (Crawford, 1959; Crompton, 1966).
Crompton (1966) identified the inflammatory cells seen beneath the endothelium and deep
in the IA wall as polymorphonuclear leukocytes (PMN), plasma cells, and small round
cells. Later, immunohistochemical analyses have verified the inflammatory cells in IA
walls to also be CD68+ macrophages, CD163+ macrophages and T-lymphocytes (T-cells),
some natural killer cells (NK-cells), and a few B-lymphocytes (B-cells) (Kosierkiewicz et
al., 1994; Chyatte et al., 1999; Kataoka et al., 1999; Frösen et al., 2004). The magnitude
of inflammatory cell infiltrations has been associated with IA rupture (Kataoka et al.,
1999; Frösen et al., 2004), stressing the role of inflammation in the degenerative processes
of the IA wall. Interestingly, macrophage infiltration has also been associated with the
proliferation of mural cells in IA walls (Frösen et al., 2004). In experimental IA studies,
macrophages have been the first inflammatory cells invading the progressing IA wall
following endothelial dysfunction (Jamous et al., 2007). Macrophages produce numerous
effectors, i.e. TGF- , reactive oxygen species (ROS), tumor necrosis factor alpha (TNF-
), and interleukin-1 (IL-1), to induce apoptotic cell death, cell proliferation and
migration, ECM production and degradation, and modulation of IA wall structures, as
reviewed in Boyle (2005). The numerous potential functions of macrophages in IA walls
are presented in Figure 3. Inflammatory cells in general likely also have more functions in
IA wall pathobiology.
The initial trigger for inflammatory cell infiltration into IAs is unknown. In
experimental IAs in rodents, macrophage infiltration follows IA formation and endothelial
dysfunction (Aoki et al., 2007a; Jamous et al., 2007). This is probably a response to
chemotaxis mediated by MCP-1 (see Section 1.5.4.1). Components of the complement
system along with immunoglobulins G and M (IgG and IgM) have also been seen in IAs
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Figure 3. Probable activators and main functions of macrophages in intracranial
aneurysms. MCP-1, monocyte chemotactic protein; SMC, smooth muscle cell; EC, endothelial
cell; Mø, macrophage; VCAM-1, vascular cell adhesion molecule; IL-1 , interleukin 1 beta; TNF- ,
tumor necrosis factor alpha; IFN- , interferon gamma; MMP, matrix metalloproteinases; TGF- ,
tissue growth factor beta; ROS, reactive oxygen species; RNS, reactive nitrogen species; SCR,
scavenger receptor; IgG, immunoglobulin G; IgM, immunoglobulin M; CRP, C-reactive protein; C,
complement system; C3a and C5a, anaphylatoxins; MHC-I and MHC-II, major histocompability
complexes I and II; T, T-cell; NK, natural killer cell.
harboring inflammatory cells (Chyatte et al., 1999). Target-bound immunoglobulins
activate the complement system, and the activated complement system is chemotactic to
inflammatory cells. The possible involvement of PMNs in recruiting macrophages and
destroying tissue enzymatically has not been verified.
The role of lymphocytes in IA wall pathobiology remains obscure. The timing of
their invasion into the IA wall during IA progression has not been verified in experimental
IA studies in animals. However, lymphocytes have a central role in acquired immunity,
and polarization of the T-cell response to cytotoxic, effector, or regulatory T-cells may
orientate the vascular wall response to inflammation in either a proliferative or
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degenerative direction. The potential functions of lymphocytes in IA walls are reviewed
more thoroughly in Section 2.2.1.
In an autopsy series of 79 unruptured IAs, (inflammatory) cell infiltrations
occurred in the fundus and were always accompanied by fibrosis. More importantly,
fibrosis was never seen without an (inflammatory) cell infiltration, suggesting it to be
secondary to inflammatory cell invasion (Crompton, 1966). Fibrosis is considered to be an
end-phase of chronic inflammatory reactions (Wynn, 2008). Fibrosis develops as a
response of SMCs and myofibroblasts to cytokines and growth factors secreted by
inflammatory and other activated cells. Macrophages are known to induce fibrosis through
secretion of TGF-  (Boyle, 2005).
1.5.4.3 Remodeling of extracellular matrix
The tensile strength of the IA wall originates from many very thin, relatively coherently
organized sublayers of collagen that collectively provide a balanced distribution for
bearing the biaxial tensile stress of the IA wall (Canham et al., 1996). However, the
distribution of the structural proteins in IAs often differs from their organization in
cerebral arteries, and their expression in immunohistochemistry is often less intense.
Moreover, in IAs, the total collagen content and the number of strength-providing
deoxypyridinoline cross-links are decreased (Gaetani et al., 1997).
Whereas normal cerebral arteries often show linear organization of different
collagens, type I, III, IV, and V collagens, and fibronectin are diffusely expressed in the
IA wall. Type IV collagen, which is normally expressed in the adventitia, is missing from
the abluminal part of the IA wall (Austin et al., 1993; Skirgaudas et al., 1996; Mimata et
al., 1997; Kilic et al., 2005). The IA wall also harbors less laminin than the normal
cerebral artery wall (Kilic et al., 2005). It also nearly lacks desmin, which is normally
expressed around medial SMCs (Mimata et al., 1997). The content of hyaluronan, a highly
hydrated anionic macromolecule and an essential component of the ECM responsible for
the viscoelastic resistance of a thinned vessel wall, is increased in IAs (Klekner et al.,
2005). Although immunostaining shows slight diminishment of type III collagen relative
to the normal control artery, in situ hybridization of the IA wall reveals its synthesis being
increased, indicating a faster turnover of collagen III in the IA wall (Mimata et al., 1997).
A definite feature related to IA wall degeneration is the disruption of its matrix.
MMPs are proteolytic enzymes expressed by SMCs and macrophages in the IA wall
(Caird et al., 2006; Aoki et al., 2007a). MMP activity can be upregulated in response to
hemodynamic factors, mechanical strain, vascular injuries, inflammatory cytokines, and
ROS (Raffetto et al., 2008). In IA patients, MMP-2 (Todor et al., 1998) has been found to
be responsible for increased serum gelatinase activity and decreased levels of serum
procollagens I and III (Chyatte and Lewis, 1997). The expression levels of membrane-type
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1 MMP (MT1-MMP) and gelatinases MMP-2 and -9 are increased (Bruno et al., 1998;
Caird et al., 2006; Jin et al., 2007) in IA walls. Also cathepsins D, G, S, B, and K,
proteolytic enzymes expressed differentially by SMCs, macrophages, leukocytes, and
endothelial cells, have been found in IAs (Kataoka et al., 1999; Aoki et al., 2008a). The
activities of proteinases are in part regulated by their endogenous inhibitors (Raffetto et
al., 2008). In IAs, levels of both TIMP (Jin et al., 2007; Jayaraman et al., 2008) and
cystatin C (Aoki et al., 2008a) are decreased, thus potentiating the effects of proteinases.
Similar changes have been seen in experimental IAs (Aoki et al., 2007b; Aoki et al.,
2008a).
IA patients have significantly higher plasma elastase levels than normal
nonaneurysmal control patients. Furthermore, elastin in hyperplastic extracranial arteries
is more deranged in IA patients than in controls (Connolly et al., 1997). However, the
disturbance in the balance of proteinases and their inhibitors is more likely local than
systemic, as IA walls have markedly increased levels of both elastase MMP-9 and its
major inhibitor TIMP (Kim et al., 1997).
In addition to proteolytic activities, MMPs may have other functions in the IAs.
MMPs are needed for vascular remodeling, cellular migration, and processing of ECM
proteins in order to provide vascular homeostasis. MMPs also have a role in the formation
of neointima, MMP-2 and -9 inhibit rat SMC contraction, MT1-MMP and MMP-2
enhance angiogenesis, and degradation of ECM by MMPs releases several angiogenic
growth factors (Raffetto et al., 2008). Thus, the balance between activation of proteolytic
enzymes and their inhibition might be critical for IA wall degeneration.
1.5.4.4 Proliferation and myointimal hyperplasia
IA wall thickness is independent of patient age or gender or aneurysm size or location
(Inagawa and Hirano, 1990), indicating that it depends on local factors. In a series of 91
ruptured IAs, SMC hyperplasia was seen in 40% (Holling et al., 2009), and the
proliferation ratio increased in ruptured IAs (Frösen et al., 2004). Moreover, stress-
induced mitogen-activated protein kinases (MAPKs) are expressed in IAs (Laaksamo et
al., 2008). They are involved in vascular remodeling, apoptosis, cell growth, and survival.
Furthermore, strong expression of the proinflammatory cytokine TNF-  in ruptured IAs
and its activity are linked to IA growth (Jayaraman et al., 2005). TNF-  can be induced by
all of the common IA risk factors (hypertension, aging, female gender, smoking, alcohol
abuse, and genetics) for IA rupture (Jayaraman et al., 2008).
Mural cells of the IA wall, mainly the SMCs, may proliferate as a response to
several growth factors detected in the IA wall. Especially VEGF, functioning in
angiogenesis, vasodilatation, and chemotaxis for inflammatory cells, is strongly expressed
in IA walls (Skirgaudas et al., 1996; Kilic et al., 2005). Expression of VEGF receptors is
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associated with IA wall rupture, vascular remodeling, T-cell and macrophage infiltration
(VEGF receptor-1), and cell proliferation and myointimal hyperplasia (VEGF receptor-2)
(Frösen et al., 2006b). The differential expression of VEGF receptors indicates multiple
alternative effects of VEGF in the IA wall. Platelet-derived growth factor (PDGF) and
bFGF seem to be expressed less in IAs than in control arteries (Ohkuma et al., 2003; Kilic
et al., 2005). In addition, the receptors for PDGF, bFGF, and insulin-like growth factor
(IGF), which promote cell proliferation, are expressed in IAs (Frösen et al., 2006b). Based
on the detected expression of different growth factors, growth factor receptors, and
MAPKs, the IA wall seems to undergo a constant remodeling process, probably in
response to inflammation and local stress.
1.5.4.5 Decellularization
The loss of medial SMCs is evident upon degeneration of the IA wall. In apoptosis, the
cells die in a programmed way as a response to death-signaling with a minimum
proinflammatory effect. Apoptotic cells have been seen especially in the necks and domes
of IAs, whereas only a few apoptotic cells have been described in control arteries (Sakaki
et al., 1997; Hara et al., 1998; Pentimalli et al., 2004; Guo et al., 2007). Apoptosis has
been associated with IA formation also in experimental settings (Kondo et al., 1998).
Moreover, necrotic cell death is seen in half of IAs (Holling et al., 2009). In contrast to
apoptosis, necrotic cell death that occurs in response to an acute injury leads to a burst of
highly proinflammatory cellular contents. The exact reasons for cellular death in the IA
wall are unknown, although many of the proinflammatory mediators present in the IA
wall, e.g. the proinflammatory cytokine TNF-  (Jayaraman et al., 2005), are known to
induce apoptotic or necrotic cell death. Proteolytic enzymes may detach the SMCs from
the surrounding ECM, leading to anoikis, another type of apoptotic cell death (Chiarugi
and Giannoni, 2008). In addition, local hypoxia has been proposed as a possible
mechanism for cell death in the IA wall (Inci and Spetzler, 2000). Notably, hypoxia would
also induce collagen synthesis (Fahling et al., 2004).
1.5.4.6 Lipid accumulation and atherosclerotic changes
Atherosclerosis has been thought to be related to IA formation (Carmichael, 1950; Walker
and Allegre, 1954). The deposition of lipids into the vascular wall, an early phenomenon
of atherosclerosis, is most frequent in the fundus of the IA. In normal cerebral arteries,
neutral lipids accumulate in the subintimal space and only rarely reach the media (Zugibe
and Brown, 1961). In IAs, lipid droplets have been seen in both the media and the
adventitia together with macrophages and intracellularly in endothelial cells, distended
SMCs, other intramural cells (Nyström, 1963), and macrophages (foam cells) (Crompton,
1966). The foam cells have been detected together with fibrin deep in the IA wall
(Crompton, 1966). Other histological changes considered to be atherosclerotic, such as
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proliferation of SMCs (Kataoka et al., 1999; Frösen et al., 2004), hyalinization of the
connective tissue (Hassler, 1961), infiltration of the media and adventitia by macrophages
(Kosierkiewicz et al., 1994; Kataoka et al., 1999; Frösen et al., 2004), vacuolization of
endothelial cells (Nyström, 1963), and intimal neovascularization (Aydin, 1998), have
also been seen in IAs.
The atheromatous changes are often focal (Rajesh et al., 2004) and seem to be
strictly localized in the aneurysm sac. They are only infrequently present in the IA neck,
while parent vessels are usually spared (Scanarini et al., 1978a). In some IAs, the
atherosclerotic changes colocalize with endothelial damage (Kataoka et al., 1999).
Advanced atherosclerotic lesions with cellular infiltrates of mostly macrophages, SMCs,
and lymphocytes are detected in 32-48% of IAs in general (Kosierkiewicz et al., 1994;
Caird et al., 2003). They are even more often seen in large IAs (Kosierkiewicz et al.,
1994). Notably, if the definition of atherosclerotic changes is strictly followed, nearly all
IAs could be considered ‘atherosclerotic’.
Apolipoprotein(a) (Apo(a)), an active moiety of lipoprotein(a), has been observed
in layers between the intimal pad and the deep aneurysmal wall and in most of the feeding
vessels (Caird et al., 2003), suggesting a more generalized phenomenon. Normal
intracranial arteries may show atherosclerotic plaques and Apo(a) (Jamieson et al., 1995).
Serum lipoprotein(a) levels are also higher in IA patients, especially in females, than in
clinically nonatherosclerotic healthy controls (Bolger et al., 1995).
Oxidative modification of lipids (and proteins) by reactive oxygen and nitrogen
species induces the formation of epitopes that can be recognized by the so-called pattern
recognition receptors (PRRs). These include CRP, complement C1q, and macrophage
scavenger receptors (Chou et al., 2008). Oxidized epitopes are also the main targets for
naturally occurring antibodies (NAbs), which mainly belongs to the IgM class (Chou et
al., 2009). The ultimate oxidation level of the tissue depends on the balance of ROS
production and destruction. ROS are produced in the arterial wall by electron leakage from
the mitochondrial respiratory chain, phagocytes’ oxidative burst (NAPDH oxidase), as a
by-product of normal cellular metabolism, and by the action of nitric oxide synthases (i.e.
iNOS and eNOS) (Szasz et al., 2007). Of the known arterial ROS producers, inducible
nitric oxide synthase (iNOS) has been found in human IA walls (Fukuda et al., 2000). In
experimental IAs, the expression of iNOS has been found to increase and that of
endothelial nitric oxide synthase (eNOS) to decrease during IA progression (Fukuda et al.,
2000). The knockout of iNOS diminishes the size of experimental IAs and the number of
apoptotic SMCs (Sadamasa et al., 2003). Recently, Aoki et al. (2009c) showed that ROS
inhibition by edavarone diminished the size of IA, IEL disruption, and macrophage
infiltration, and enhanced the medial thickness of rat experimental IAs. These effects
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occurred, probably through inhibition of NF B and the consequent decrease in expression
of MCP-1, VCAM-1, and MMP-2.
1.5.4.7 Thrombus
The presence of an organizing thrombus is frequently seen in ruptured IAs (Schlote and
Gaus, 1994; Frösen et al., 2004). The organizing thrombus often carries thin-walled
capillaries, fibroblasts, and minimal amounts of extracellular mucoid material (Rajesh et
al., 2004). Normally, the intact and healthy endothelium protects the luminal surface of
the vascular wall from thrombosis and platelet aggregation by the expression of CD39 and
secretion of nitric oxide (NO) and prostacyclin (Watson, 2009). The coagulation cascade
may be initiated by a local endothelial injury or by a release of inflammatory mediators
from damaged or stressed endothelial cells (Wynn, 2008). In total endothelial injury, also
the subendothelial prothrombotic structures that come into contact with platelets facilitate
activation of the coagulation cascade and thrombus formation. Altered hemodynamics and
decreased blood flow promote endothelial dysfunction and thrombus formation (Wohner,
2008). Both erythrocytes and platelets become trapped in the fibrin meshwork of a fresh
thrombus. Chemotactic signals and expression of adhesion molecules aid neutrophil and
macrophage infiltration into the site of injury (Wohner, 2008; Wynn, 2008).
To promote fibrinolysis and thrombus deformation, platelets and neutrophils
secrete MMPs, cathepsin G, and elastase. The proteolytic enzymes released by neutrophils
and macrophages are probably involved in further degradation of the IA wall as well as in
the induction of anoikis (Fontaine et al., 2002; Fontaine et al., 2004). Later, the
inflammatory cells may migrate into an IA wall as PMNs, and other inflammatory cells
have been found in the IA wall (Hassler, 1961; Crompton, 1966). A thrombus begins to
organize by invading cells, SMCs, or myofibroblasts that originate at least in part from the
vascular wall (Frösen et al., 2006a; Lee et al., 2007; Wynn, 2008). The thrombus
subsequently becomes an indistinguishable part of the IA wall.
1.5.4.8 Summary of mechanisms altering intracranial aneurysm wall
structure
Both degenerative and reparative mechanisms seem to operate in the IA wall. The likely
mechanisms leading to IA progression and critical thinning of the IA wall are summarized
in Figure 4. They are based on combined data from studies on human and experimental
IAs.
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Figure 4. Mechanisms likely leading to IA progression and critical thinning of the IA wall. An
aneurysm forms at the site of disrupted internal elastic lamina (IEL) (1)  associated with myointimal
hyperplasia (2). Hemodynamic stress, primary or secondary to the structural modifications of the
vascular wall, leads to endothelial dysfunction (3) and chemotaxis for invasion of macrophages
and/or other leukocytes (4). At the same time, matrix synthesis is increased to support the tensile
strength of the aneurysm wall due to function of growth factors secreted by, for instance,
macrophages (5). However, because of the cytotoxic milieu caused by inflammatory cells,
increased matrix, and possibly decreased oxygen supply arising from an increased wall thickness,
the mural cells start to die (6). Matrix turnover slows down due to decreased production secondary
to decellularization and increased lysis by the action of matrix metalloproteinases (MMPs) (7).
Over time, as the aneurysm wall becomes mechanically more fragile, it finally ruptures when the
intraluminal pressure overcomes the tensile strength. Lymphocytes also have an important role in
aneurysm wall degeneration by guiding the immune response and the surveillance of mural cells.
However, their timing in aneurysm progression is unclear (X). Depending on the hemodynamics
and shear stress, the endothelium may die or severely dysfunction, leading to thrombus formation
(8). In addition to other inflammatory cells, the thrombus attracts neutrophils (9), which are potent
producers of proteolytic enzymes. Over time, the thrombus may become organized by migrating
mural cells (10). However, due to cell death and decreased matrix turnover, the aneurysm wall
becomes fragile enough to rupture. This figure is a simplification of the pathobiological processes
within the aneurysm wall. Thus, it does not represent all factors with potentially crucial roles in
aneurysm wall degeneration, e.g. complement activation, lipid accumulation, and
neovascularization.
1.5.5 Role of extra-aneurysmal factors
During IA formation the hemodynamics in the IA changes. Blood flow inside the IA has
two components: pressure and shear stress to the IA luminal surface. In a follow-up study
of 7 IA patients by MR-angiography, aneurysm growth and development of
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atherosclerotic plaques were shown to be related to low local wall shear stress (Boussel et
al., 2008; Tateshima et al., 2008). Laminar flow is required for endothelial survival
(Chien, 2008). Excessively high or low shear stress affects the endothelium and induces
endothelial dysfunction. Smooth muscle cells are also sensitive to shear stress and stretch
(Zou et al., 1998). Thus, flow conditions in IAs affect the biology of the IA wall.
IAs grow into the subarachnoidal space, composed of arachnoideal strains and
spaces filled by cerebrospinal fluid. In general, the extra-arterial pressure most likely
affects the cellular organization of the cerebral artery wall, and thus, IA wall modification.
In experimental settings, decreased intracranial pressure allows the cerebral artery wall to
become thicker and lose the tight packing of linearly organized SMCs (Hassler, 1961).
The perianeurysmal environment, serving to constraint contact between the IAs and
anatomical structures, mechanically influences the IA shape and rupture. When optimally
positioned, contact constraints can have a protective effect, as they may decrease the
stresses near the IA fundus (Seshaiyer and Humphrey, 2001). The contact constraints of
ruptured IAs and the perianeurysmal environment are more unbalanced than those of
unruptured IAs, allowing ruptured IAs to grow larger and irregular in shape (San Millan
Ruiz et al., 2006).
1.5.6 Role of intrinsic and acquired risk factors
Hypertension
Vascular hypertension has been proposed to affect the IA wall by three different
mechanisms: by inducing endothelial injury, by promoting occlusion of the vasa vasori,
and by disturbing the synthesis of elastin and collagen (Inci and Spetzler, 2000).
Hypertension is also known to induce TNF-  expression, which affects IA growth and
may initiate degenerative changes at the cellular level (Jayaraman et al., 2008).
Experimental IAs can only be induced by disturbed hemodynamics (Hashimoto et al.,
1984; Stehbens, 1989).
Smoking
Smoking (also passive) is proinflammatory, as it induces inflammatory injury by
increasing VCAM-1, MCP-1, and IL-8 expression in the subendothelial and medial layers
of the arterial wall (Zou et al., 2009). Cigarette smoke also downregulates lysyl oxidase,
an enzyme initiating cross-linkage between elastin and collagen, in fibroblasts (Chen et
al., 2005). It also increases the metalloproteinase activity of rat plasma and human
fibroblasts (Machida et al., 2004; Yin et al., 2000) and decreases collagen I and III
synthesis (Yin et al., 2000). At least part of the effects of cigarette smoke on cellular
function might be mediated through induction of a nonfunctional form of TGF- 1 and
II Review of the literature
31
downregulation of the TGF- 1 receptor (Yin et al., 2003). The modifications on type IV
collagen by cigarette smoke and lipid peroxidation products trigger macrophages by their
type A scavenger receptor and promote MCP-1 release and oxidative burst from
macrophages (Kirkham et al., 2003).
Female gender
Decreasing circulating estrogen levels and a probable decrease in expression of estrogen
receptors have been suggested as mechanisms for IA progression in women (Harrod et al.,
2006). Estrogen receptors are important modulators of the vascular wall. In vascular
injury, estrogen acts as an anti-inflammatory, as it inhibits the local induction of
proinflammatory mediators and adhesion molecules, leukocyte activation, infiltration, and
accumulation, adventitial activation and local release of cytokines, and remodeling of
matrix proteins (reviewed by Xing et al., 2009). In an experimental setting, estrogen
deficiency caused an increased incidence and size of experimental IAs, probably by
endothelial dysfunction and associated ROS generation, whereas estrogen replacement
therapy counteracted the effect (Jamous et al., 2005a; Jamous et al., 2005b; Tamura et al.,
2009).
Aging
Aging causes many changes in tissue structures and cellular functions in general. Cerebral
arteries also undergo changes with age. The relative proportion of different fibers in elastic
lamina is altered gradually, with collagen becoming more abundant, and with the
appearance of type 3 pseudoelastic fibers the arterial wall losing its elasticity (Hegedus
and Molnar, 1989). Accumulation of neutral lipids within IEL and intima along with the
expression of acid mucopolysaccharides also becomes more abundant with age (Zugibe
and Brown, 1961). The total lipid concentration increases and the relative amounts of
different glycosaminoglycan change (Murata, 1985). In the elderly, the effect of acquired
risk factors accumulates.
Alcohol and drug abuse
Heavy alcohol use is a common cardio- and cerebrovascular risk factor for hemorrhagic
(SAH) and ischemic strokes as well as cardiomyopathy. Although the exact cellular
mechanisms underlying alcohol abuse-altering arterial homeostasis are widely unknown,
increased blood pressure related to alcohol intoxication and alterations in cerebral artery
tone are thought to promote the degeneration of the cerebral artery wall (Hillbom, 1998).
Cocaine, in turn, may cause a severe elevation in blood pressure, vasospasm, and
vasculitis. Naturally, some of the IAs in cocaine users may also be mycotic in origin due
to intravenous administration of the drugs (Neiman et al., 2000).
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1.6 Molecular pathology of intracranial aneurysms
Genetic background plays a role in IA pathobiology, as different nationalities have
different rates of aSAH. Even rat species differ in their susceptibility to IAs. The genetic
variation is evident, as of the several susceptible gene loci only four (1p34.3-p36.13, 7q11,
19q13.3, and Xp22) have been replicated in different populations (reviewed in Ruigrok
and Rinkel, 2008). Recently, the susceptibility locus 19q13.3 for Finnish and Japanese
populations (van der Voet et al., 2004; Mineharu et al., 2007) remained unconfirmed in
another study of Finnish, Japanese, and Dutch cohorts (Bilguvar et al., 2008).
Several candidate genes are included in the IA susceptibility loci. However, the
linkage studies of their associations have yielded varying results depending on the study
population (Krischek and Inoue, 2006). Of these, the genes for IL-1 , collagen type I and
III, elastin, eNOS, endoglin, angiotensin-converting enzyme, MMP-9, and heme-
oxygenase 1 have revealed positive associations. Several candidate genes for IAs have
also been investigated at the level of single-nucleotide polymorphisms (SNPs), with
varying results depending on the study population.
2 Inflammation in the vascular wall
Inflammation is a normal tissue’s reaction to physical, chemical, or biological stress or
injury. It is manifested as activation of innate immune response, release of inflammatory
mediators, and inflammatory cell accumulation. The classical clinical symptoms caused by
inflammatory reaction – rubor (redness), calor (heat), tumor (swelling), and dolor (pain) –
are also seen during microbial infections, where inflammation has an important role as a
defense mechanism against invading microbes. However, in most acute and chronic
inflammatory diseases, the inflammatory reaction occurs aseptically, i.e. in the absence of
microbes. In aneurysms, similarly to atherosclerosis, the inflammatory reaction has
become persistent and chronic. As there is no evidence of a persistent infection in IAs
(excluding the rare cases of mycotic aneurysms), the next sections focus on the
inflammatory mechanisms responding to apathogenic irritants.
Inflammatory reactions are mediated by the immune system, which can be broken
down into two responses: innate and adaptive immunity. The division is based on the
ability to respond to certain surface structures either inherently (innate immunity) or by
modification of the response by genetic rearrangements (adaptive immunity). In practice,
both arms of immunity are usually involved in the inflammatory reaction, and they act in
concert with each other. The complement system, an ancient immunological defense
mechanism, is a core element of the innate immune response, also having an important
role in directing adaptive immune responses.
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2.1 Inflammation and immunity
Inflammation is a normal response to tissue trauma or irritants, whether microscopic or
macroscopic, and necessary for removing the irritant and for healing to occur. The innate
immune system recognizes the irritant and/or the trauma and recruits inflammatory cells
(polymorphonuclear leukocytes and monocytes) to the site of inflammation. The
recognition is based on the inherent ability of certain molecules (pattern recognition
receptors, e.g. complement components, acute phase proteins, toll-like receptors (TLRs),
and macrophage scavenger receptors (SCRs)) to bind certain molecular patterns, leading
to further activation of innate immunity. Antibodies may as well be involved in the
recognition of harmful stimuli (Chou et al., 2008). At an early stage, the trauma activates
also the coagulation cascade, promoting the inflammatory reaction by, for example,
platelet degranulation (Wynn, 2008).
Cytokines, chemokines, and growth factors secreted mainly by inflammatory cells
create a milieu that favors healing of the injury. Cytokines produced by the innate
inflammatory cells are also chemotactic to the cells of the adaptive immunity
(lymphocytes; T-cells, B-cells). If adaptive immunity cells become activated, they can
further affect the nature and outcome of the inflammatory reaction by secreting cytokines
and/or producing antibodies. Fibrosis and neovascularization are important late-stage
processes in the route to complete healing. Fibrosis, promoted by myofibroblasts, takes
place to restore mechanical strength at the site of injury and to build an ECM framework
for migrating cells. Neovascularization, in turn, provides the newly formed tissue with a
sufficient supply of oxygen and nutrients (Beutler, 2004; Stavitsky, 2007; Wynn, 2008).
As inflammatory cells and chemical mediators also have the potential to harm
uninvolved, healthy tissue beyond the trauma, the inflammatory reaction is tightly
controlled and healthy tissues are protected by several inhibitors. If control of the
inflammatory reaction fails, it may lead to various diseases depending on the site and
failed mechanisms, e.g. glomerulonephritis, acute pancreatitis, vasculitis, angioedema,
hemolysis, disseminated intravascular coagulation, and shock.
2.1.1 Acute and chronic inflammation
Acute inflammation is the initial response to harmful stimuli, where characteristically the
innate immunity, with an inherent ability to recognize the stimuli and react fast, is
recruited. After removal of the irritant, aided by the acquired immunity, the injured tissue
heals and the inflammation ceases in the shortage of proinflammatory mediators.
However, if the immune system cannot overcome the irritant, the acute inflammatory
reaction becomes chronic, as seen in atherosclerosis, rheumatoid arthritis, and psoriasis. In
chronic inflammation, tissue healing and destruction occur simultaneously, leading to
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permanent changes in the tissue causing the disease phenotype. Remarkably, in the case of
autoimmune diseases and possibly also in other chronic inflammatory diseases, the
inflammatory mechanisms themselves may maintain the problem and cause the tissue
destruction.
2.2 Innate and adaptive immunity
The innate immune system has an inherent ability to recognize and become activated by a
wide range of molecular patterns, to respond quickly to activation, and to act in a targeted
fashion against the activating stimulus, sparing otherwise healthy tissues. The activating
molecular patterns or individual molecules often resemble surface antigens found on
pathogens, and are thus called pathogen-associated molecular patterns (PAMPs). The
majority of PAMPs arise from oxidative modification of proteins and lipids or from cell
death. PAMPs are recognized by TLRs, complement components, naturally occurring
immunoglobulins, and SCRs. Antibodies and complement factors (C1q, C3b, iC3b, MBC,
ficolins) are, in turn, recognized by Fc receptors and complement receptors (Chou et al.,
2008). The cellular components of the innate immunity are polymorphonuclear
phagocytes (neutrophils, basophils, and eosinophils), and mononuclear phagocytes
(macrophages and dendritic cells) that are recruited to the site of inflammation by
chemokines originating from the activated complement system, other inflammatory cells,
or parenchymal or endothelial cells. Of the polymorphonuclear phagocytes, neutrophils
are specialized in target destruction and opsonophagocytosis, whereas eosinophils and
basophils are mainly involved in the production of inflammatory mediators in response to
cytokines of the adaptive immune system (Beutler, 2004).
Innate immunity can be regarded as primitive and inherent in nature. Adaptive
immunity, in turn, is acquired, requiring prior activation and modulation by the innate
immunity system. Adaptive immunity cells comprise B-lymphocytes (B-cells) and T-
lymphocytes (T-cells), to which the antigen is presented by macrophages, dendritic cells,
and B-cells. B-cells develop into plasma cells that can produce specific antibodies. The
function of T-cells depends on their phenotype: cytotoxic CD8-positive T-cells secrete
mainly proinflammatory cytokines. The actions of CD4-positive T-cells at the site of
inflammation depend on their differentiation into either proinflammatory effector T-cells
(Th1 or Th17), humoral immunity-promoting Th2 cells, or immunosuppressive regulatory
T-cells (Th3 or Tr1). This differentiation is largely determined by the local cytokine
milieu. In addition to the cytokines present, the natural killer cells (NK cells), and the
regulatory T-cells (Treg), the adaptive immune response is facilitated by the complement
system (Carroll, 2004b; Kemper and Atkinson, 2007). The covalent binding of
complement opsonins to antigens reacting with B-cells leads to a more efficient antibody
production. In addition, complement activation affects cytokine production by antigen-
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presenting cells (APCs), further directing the T-cell response. As most IgGs are products
of the adaptive immune system, complement activation through the classical pathway in
response to the antigen-bound IgG can be considered an adaptive immune response. The
interactions between innate and adaptive immune systems are outlined in Figure 5.
Figure 5. Interactions between innate and adaptive immunity. Pw stands for pathway.
2.2.1 Inflammatory cells
Many types of inflammatory cells are present in the IA wall, and some are associated with
IA rupture. These include macrophages, T-cells, B-cells, plasma cells, NK cells, and
PMNs. The nature of these cells is briefly described in the following sections.
Macrophages
Macrophages are inflammatory cells that differentiate from blood monocytes at the site of
inflammation. They are a morphologically diverse group of cells expressing a varying
repertoire of surface antigens and receptors. To recognize the PAMPs, macrophages
express SCRs and TLRs (Chou et al., 2008). The antigen-bound immunoglobulins are
recognized through Fc receptors, and the complement activation products (opsonins and
anaphylatoxins) through C1qR, CR1, CR2, CR3, C3aR, and C5aR (Morgan and Gasque,
1997). Activation of macrophage receptors can lead to the production of cytokines (e.g.
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IFN- , TNF- , IL-1 , IL-6, and IL-8) and growth factors (e.g. TGF- ) to recruit other
inflammatory cells to the site of inflammation and to modulate the tissue’s response to
injury for healing purposes (Figure 3) (Osterud and Bjorklid, 2003). Thus, although
macrophages are also capable of killing microbes in infections, their most important
function is supervisory. Interestingly, the reactive oxygen and nitrogen species produced
for killing purposes are also cytotoxic to viable cells and may modulate proteins and lipids
to become proinflammatory (Chou et al., 2008). Moreover, macrophages express major
histocompability complex (MHC)-I and II molecules, through which they introduce
phagocytosed and processed antigens to T-cells (Beutler, 2004). MHC-I- and II-expressing
macrophages have been detected in IAs, some of them in close contact with T-cells
(Kosierkiewicz et al., 1994). In general, macrophage infiltration is associated with IA
rupture (Kataoka et al., 1999; Frösen et al., 2004).
Dendritic cells
Dendritic cells are phagocytic cells that present antigens on MHC-II to activate T-cells
(Beutler, 2004). They also express CD1d, needed for activation of NK cells (Bobryshev
and Lord, 2002). Dendritic cells have been shown to be present in the periadventitial tissue
of extracranial arteries (Millonig et al., 2002). However, as dendritic cells share common
receptors used for detecting macrophages in immunostainings, the presence of dendritic
cells in IAs has remained uncertain.
T-lymphocytes
T-lymphocytes are classified into cytotoxic CD8-positive T-cells (Tc-cells) and CD4-
positive helper T-cells that can be further classified as proinflammatory effector T-cells
and immunosuppressive regulatory T-cells. The functions of T-cells depend on their
phenotype. Tc-cells can secrete proinflammatory cytokines interferon gamma (IFN- ) and
tumor necrosis factor alpha (TNF- ), and may also induce apoptosis by a Fas ligand-
dependent interaction. The actions of effector and regulatory T-cells depend on their
differentiation into the direction of Th1, Th17, Th2, Th3, Tr1, or Treg. IL-12, IL-23, or IL-1
differentiates effector T-cells into either the Th1 or Th17 direction, whereas the regulatory
Th2-phenotype occurs in the presence of IL-4. Regulatory Tr1 differentiation requires IL-
10 or IFN- . The differentiation of regulatory Th3 cells requires the presence of several
cytokines (van Roon et al., 2006; Romagnani et al., 2009). The subtypes of effector and
regulatory T-cells differ in their functions depending on the cytokines produced upon
activation. The activation and polarization of an adaptive immune response and the main
functions of different T-cell subtypes are summarized in Figure 6. T-cells are also
responsive to complement activation, as they express several receptors (CR1, CR2, CR4,
C3aR, CD46, CD55, and CD59) for complement components and anaphylatoxins that
regulate T-cell activation, proliferation, and cytokine production (Morgan and Gasque,
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1997; Kemper and Atkinson, 2007). Human IAs harbor T-cells, and T-cell infiltration in
general is associated with IA rupture.
Figure 6. Potential T-cell differentiation and activation mechanisms and functions in
intracranial aneurysms. An antigen-presenting cell (APC) presents antigens in a specific groove
of its major histocompability complex I or II (MHC-I or MCH-II) molecules depending on the nature
and origin of the antigen. T-cell recognizes antigen and MHC through T-cell receptor (TCR) and
CD4 (helper T-cells, Th) or CD8 (cytotoxic T-cells, Tc). Activated T-cells secrete many cytokines
and inflammatory mediators (e.g. interferon gamma, IFN- ; tumor necrosis factors alpha and beta,
TNF-  and TNF- ; transforming growth factor beta, TGF- ; and interleukins, IL) that further guide
the inflammation in the aneurysm wall. The polarization of Th-cells into the effector (Th1 or Th17) or
regulatory (Th2, Th3, Tr1, or Treg) direction depends on the presence of distinct sets of interleukins.
Natural killer T-lymphocytes (NKT) play an important role in this process, as they can guide the
polarization by secreting either IFN-  or IL-4. The regulatory T-cells (Treg) and the naturally
occurring regulatory T-cells (nTreg) function by a direct cell-cell interaction. Note that T-cell
regulation is a complex process, and only the most important mediators are presented here. T-cell
regulation is also a flexible system and this figure represents a simplification of the current view.
B-lymphocytes
B-cells are lymphocytes that mediate humoral immune response by differentiating into
antibody-producing plasma cells or memory B-cells. They can also act as APCs. B-cells
become activated through an antigen-receptor interaction independently or by
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costimulation of Th2 cells. In addition to the B-cell receptor (BCR), B-cells express
receptors for complement components C3d and C3b (CD21 and CD35), which aid in
antigen recognition and stimulate antibody production (Carroll, 2004b). After activation,
the B-cell undergoes clonal expansion and eventually develops into a memory B-cell. The
cytokines from Th2 cells promote B-cell progression into plasma cells that secrete soluble
antibodies (Manz et al., 2006). Both B-cells and plasma cells have been detected in IA
walls (Crompton, 1966; Chyatte et al., 1999).
Natural killer cells
Natural killer cells differ from other lymphocytes in that they produce cytokines in
response to antigens presented in the CD1 molecule. NK cells kill virus-infected cells and
tumor cells, which lack or have low levels of MHC-I expression. The main cytokines
produced by NK cells are IL-4 and IFN- , and thereby, NK cell can direct the T-cell
response into either a Th1 or Th2 direction. NK cells have been detected in human IAs
(Kosierkiewicz et al., 1994).
Polymorphonuclear leukocytes
Polymorphonuclear leukocytes (PMNs) are also called granulocytes due to their
cytoplasmic contents of granules containing degrading enzymes and substances that shape
the inflammatory milieu. PMNs are divided into basophils, eosinophils, and neutrophils
according to the morphology of the nucleus and the contents of the granules (Beutler,
2004; Kennedy and DeLeo, 2009). As eosinophils and basophils are mainly involved in
parasitic infections, they will not be discussed in more detail here. Basophils may also
function in directing the Th2 immune response by IL-4, but this and other possible
basophil-mediated mechanisms remain poorly understood (Beutler, 2004; Min, 2008).
Neutrophils are the most abundant polymorphonuclear leukocytes and especially
important in first-line immune defense. They are primed and recruited to the site of
inflammation and/or tissue injury by released inflammatory mediators and by, for
example, activated complement. The extravasation (trans-endothelial migration) is also
mechanically aided by endothelial expression of selectins. Neutrophils contain and secrete
many cytotoxic molecules that can cause significant damage to host tissues. They also
produce ROS and phagocytose the opsonized or PAMP-expressing particles through PRR-
mediated recognition (Kennedy and DeLeo, 2009). In tissues and circulation, neutrophils
are short-lived, undergo spontaneous death, and become phagocytosed by macrophages in
order to maintain homeostasis of the immune system (Savill et al., 1989; Beutler, 2004).
Even in the presence of proinflammatory cytokines (e.g. IL-1 , TNF- , IFN- ), which
prolong neutrophil survival, they remain viable for only up to two days (Kennedy and
DeLeo, 2009).  As neutrophils die, they may release matrix-degrading enzymes (i.e.
cathepsin G, elastase, protease-3, MMP-9) and other granule proteins to the surroundings,
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thus inadvertently promoting the inflammation.  The granule proteins together with MCP-
1 are chemoattractants to monocytes, T-cells, and dendritic cells (Soehnlein et al., 2009).
2.3 Complement system
The complement system is a first-line defense mechanism with a central role in the innate
immune response. Complement also regulates adaptive immunity by activation and
stimulation of inflammatory cells. Complement participates in the removal of foreign
substances and cell debris via opsonization and strongly enhances adaptive immune
responses by, for instance, antigen delivery. Activation of the complement system leads to
the production of anaphylatoxins C3a and C5a, which are chemoattractants for leukocytes
and generate an inflammatory reaction.
Complement becomes activated in a cascade-like manner by three optional
activation pathways – classical, alternative, and lectin – depending on the activating
factor. A particular role of the ‘alternative pathway’ is to amplify complement activation
in areas lacking sufficient regulatory activity (Meri and Pangburn, 1990a). Complement
may become activated via the ‘classical pathway’ in response to endogenous ligands such
as immunoglobulins (e.g. antigen-bound IgG or IgM), pentraxins (e.g. CRP), dying cells
(apoptotic, ischemic, or necrotic), and ECM proteins. The ‘lectin pathway’ is activated by
surfaces rich in acetylated oligosaccharides or mannan. The ‘alternative pathway’
becomes activated by a surface that lacks complement inhibitors, e.g. by bacteria and
lipopolysaccharides. In addition, cholesterol-containing lipids and enzymatically or
oxidatively modified low-density lipoproteins, which may accumulate in the walls of
stressed blood vessels, e.g. in atherosclerosis, are capable of activating complement.
If not inhibited, complement activation leads to the formation of a C3-convertase,
activation of the ‘terminal pathway’, and formation of terminal complement complexes
(TCCs) or membrane attack complexes (MACs) (Figure 7). TCCs can be noncytolytic
complexes where the binding of soluble inhibitors, S-protein (vitronectin), or clusterin has
prevented the formation of a polymeric C9 pore (SC5b-9) or cytolytic MAC. MAC
consists of the C5b-8 protein complex and a varying number of C9 proteins that
polymerize and form lytic pores on cell membranes. Formation of MAC may induce cell
death or activate cells by proinflammatory mechanisms, e.g. by increasing Ca2+ influx into
cells. Because of the tendency to cause cell damage, complement activation is strongly
regulated by soluble and membrane-bound proteins (Cole and Morgan, 2003; Bohana-
Kashtan et al., 2004; Sim and Tsiftsoglou, 2004; Sjöberg et al., 2009). Complement
activation has been shown to occur in various vascular inflammatory diseases, e.g.
atherosclerosis and abdominal aortic aneurysms, and is associated with tissue degeneration
and inflammatory cell infiltration (Capella et al., 1996; Niculescu and Rus, 1999; Oksjoki
et al., 2003b; Kostner, 2004; Szeplaki et al., 2009). Apparently, the complement system is
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involved in the pathogenesis of these vascular diseases, but the reasons for complement
activation and its consequences are poorly understood.
Figure 7. Simplified presentation of complement activation. The complement activation by
either classical or lectin pathway, and activation or amplification by alternative pathway leads to
formation of C3/C5 convertases, which activate the terminal pathway leading to the formation of
the terminal complement complex (TCC) or the membrane attack complex (MAC). Opsonins and
anaphylatoxins form as split products of the activated complement components C3, C4, and C5.
2.3.1 Complement activation
The complement system consists of approximately 35 proteins, which become activated in
a cascade-like manner through sequential proteolytic cleavages and formation of protein
complexes. The classical pathway is activated by C1q-mediated recognition of the target,
which may be a tissue structure or another pattern recognition receptor, e.g.
immunoglobulin or CRP. After binding to a target, C1q changes its conformation,
triggering self-activation of C1r, which in turn activates C1s, responsible for the cleavage
of C2 and C4 (Arlaud et al., 2002). The cleavage of C4 causes C4b and its cleavage
product iC4b to accumulate in tissues. C4b binds to C2 to generate C4b2a, the C3
convertase enzyme of the classical pathway. The same enzyme acts as a C5 convertase.
The C2a component of the convertase is responsible for the serine protease activity in
cleavage of C3 and C5. Activation of the lectin pathway is initiated analogously by
activation of mannan binding lectin (MBL) or ficolins, followed by activation of the
MBL-associated serine protease MASP-2 (and possibly MASP-1), leading to cleavage of
C2 and C4.
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The alternative pathway undergoes constant turnover in the fluid phase. The
spontaneous hydrolysis of C3 generates C3(H2O), which then forms the C3(H2O)Bb
complex with the cleavage fragment of factor B. The C3(H2O)Bb complex has C3
convertase activity on C3, and new C3bBb enzymes cleave further C3 molecules. This
spontaneous “tickover” enables fast alternative pathway amplification by (bacterial)
lipopolysaccharides or by a self-surface lacking sufficient regulatory activity (Meri and
Pangburn, 1990a). Moreover, the C3/C5 convertases formed by activation of the classical
or lectin pathways are responsible for initiating amplification of the alternative pathway by
cleaving C3. After cleavage of C3, the additional binding of C3b to the C3bBb complex
generates C5 convertase activity. Bb in the C3Bb complex originates from a cleavage of
factor B by factor D and is responsible for the serine protease activity of the complex. The
alternative pathway activation or spontaneous amplification via C3/C5 convertases results
in the deposition of surface-bound cleavage products C3b/iC3b and C3d. By being the
end-product of C3b cleavage, C3d remains covalently bound to tissues, indicating
prolonged complement activation (Davis et al., 1984; Nakagawa et al., 2000).
The C3/C5 convertases activate the terminal pathway by cleaving C5 to C5a and
C5b. C5b forms a complex with C6, C7, C8, and up to 12 C9 components. Upon
formation of the C5b-9 complex, the binding of the latter component is enabled by a
conformational change in the former. The forming C5b-9 complex may remain soluble by
binding to vitronectin (S-protein) or clusterin (ApoJ). Otherwise, the C5b-9 complex is
inserted into the cell membrane as a membrane attack complex (MAC), a lytic
transmembranous pore. When MAC formation on a target membrane is massive and
uncontrolled, the target cells lyse and die. However, sublytic concentrations of MAC may
still affect the cell fate by inducing apoptosis or proliferation (Sim and Tsiftsoglou, 2004;
Sjöberg et al., 2009). Complement activation and actions of the regulators are described in
detail in Figure 8.
Opsonins
Binding of complement components to the surfaces of self-particles, immune complexes,
or pathogens opsonizes the target for phagocytic cells. The opsonins of complement origin
are recognized by several membrane-bound complement receptors (CRs) (Sim and
Tsiftsoglou, 2004; He et al., 2008; Sjöberg et al., 2009). In addition to complement split
products, also immunoglobulins act as opsonins through recognition of macrophage Fc
receptors. The traditional complement opsonins are covalently bound C3b and C4b as well
as their inactivated forms iC3b and iC4b, cleaved from C3b and C4b by factor I. Some of
the complement receptors, such as CR1 (CD35), also recognize the surface-bound C1q or
MBL. C3b and C4b are recognized by CR1, which has the main function of capturing
immune complexes to erythrocytes for transport to the spleen (Cornacoff et al., 1983).
CR2  (CD21),   which  recognizes   the  C3dg  fragment,  lowers   the  threshold  of  B-cell
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Figure 8. Activation pathways of the complement system. The figure was created by Matti
Laine.
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activation, thereby enhancing B-cell immunity and survival (Matsumoto et al., 1991;
Carter and Fearon, 1992; Carroll, 2004a). CR3 and CR4 are transmembranous
heterodimers composed of an alpha subunit (CD11b or CD11c, respectively) and a
common beta chain (CD18). In addition to orchestrating phagocytosis of iC3b-opsonized
particles, they also have functions in leukocyte trafficking and migration (reviewed by He
et al., 2008). CRIg on tissue macrophages binds C3b, iC3b, and C3c (Wiesmann et al.,
2006) for the ingestion of complement-opsonized particles (Helmy et al., 2006). As
complement receptors may activate intracellular signaling pathways during phagocytosis
(Rutherford and Schenkein, 1983; Couturier et al., 1990; Thieblemont et al., 1995), the
complement opsonins may have a more versatile role in inflammation than earlier
recognized.
Anaphylatoxins
During complement activation C3/C5 convertase cuts off small fragments from C3, C4,
and C5, producing C3b, C4b, and C5b. The small fragments, C3a, C4a, and C5a, are
collectively called anaphylatoxins. In addition to the action of the C3/C5 convertases,
anaphylatoxins may be generated also by the serine protease activity of coagulation factors
FXa and FXIa or thrombin as well as by plasmin, a serine protease of the fibrinolytic
system (Huber-Lang et al., 2006; Amara et al., 2008). Interestingly, also phagocytic cells
are capable of generating biologically active C5a (Huber-Lang et al., 2002).
Anaphylatoxins are chemotactic to phagocytes, cause vasodilatation probably by an
endothelial NOS-dependent mechanism (Park et al., 1999; Kurizaki et al., 2004), increase
the permeability of small blood vessels, and induce contraction of smooth muscle cells
(reviewed by Klos et al., 2009). The effects of C3a and C5a are mediated by binding to
specific C3a, C5a, and C5L2 (C5a receptor-like 2) receptors. A functional receptor for
C4a has not been recognized. On inflammatory cells, the anaphylatoxins C3a and C5a
trigger an oxidative burst, histamine release from basophils and mast cells, and adhesion
and migration of eosinophils, and also modulate synthesis of IL-6 and TNF-  from B-cells
and monocytes (Klos et al., 2009). Anaphylatoxins are able to induce the endothelial
expression of cell adhesion molecules VCAM-1, intercellular adhesion molecule (ICAM-
1), and selectins (Foreman et al., 1996; Albrecht et al., 2004; DiScipio and Schraufstatter,
2007). C5a may activate the exogenous coagulation pathway by inducing tissue factor
(TF) activity in endothelial cells (Ikeda et al., 1997; Amara et al., 2008). Anaphylatoxins
also regulate tissue degeneration and fibrosis (Klos et al., 2009). To some extent,
anaphylatoxins may also act in an autocrine manner, as the APCs within allograft-induced
inflammation as well as T-cells synthesize and cleave C3 to C3a (reviewed by Klos et al.,
2009). Both C3a and C5a receptors have been detected in smooth muscle cells, T-cells,
macrophages, and endothelial cells within atherosclerotic lesions (Oksjoki et al., 2007).
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2.3.2 Regulation of complement activation
Complement C3 convertase enzymes have catalytic activity, but are intrinsically unstable
(T½ 1-3 min). Due to the potentially harmful effects of complement activation on host
tissues, the activation is regulated by several soluble (C1-INH, C4bp, fH, FHL-1,
clusterin, and vitronectin) and membrane-bound (CR1, MCP, DAF, and protectin)
regulators.
C1 inhibitor
C1 esterase inhibitor (C1-inhibitor; C1-INH) is a heavily glycosylated single-chain
polypeptide of 105 kDa, with a plasma concentration of 240 g/ml (Schapira et al., 1985;
Nuijens et al., 1989). Cells including fibroblasts, monocytes, macrophages, and
endothelial cells as well as hepatocytes are responsible for synthesis of C1 inhibitor
(reviewed by Caliezi et al., 2000). Being an acute phase protein, its synthesis is induced
by several proinflammatory cytokines such as IFN- , TNF- , IFN- , monocyte colony-
stimulating factor, and IL-6. However, C1 inhibitor can be inactivated by elastase and
proteinase 3 as well as by thrombin and plasmin, e.g. in an inflammatory process. C1
inhibitor is a naturally occurring serine protease inhibitor of C1r and C1s and also controls
MASP-1 and MASP-2 within the lectin pathway. C1 inhibitor inhibits C1r and C1s either
by binding them and inhibiting their autoactivation or by dissociating them from C1q in
the C1 complex (Sim et al., 1979; Sim et al., 1980; Liszewski et al., 1996). In addition to
the complement system, C1 inhibitor also inhibits the contact system (FXIIa and
kallikrein), intrinsic activation of the coagulation system (FXIa), and fibrinolysis
(plasmin). The presence of glycosaminoglycans enhances complement inhibition by C1
inhibitor (reviewed by Caliezi et al., 2000).
C4b binding protein and protein S
C4b binding protein (C4bp) is a large glycoprotein (570 kDa) synthesized mainly by the
liver, although synthesis by, for instance, monocytes can occur under certain conditions
(Dahlback and Muller-Eberhard, 1984; Lappin and Whaley, 1990). Together with factor
H, C4bp is the main soluble complement inhibitor, found in plasma at a concentration of
200 g/ml (Dahlback, 1983). However, C4bp is an acute phase protein, whose levels in
blood may increase up to 400% during an inflammatory response (Rezende et al., 2004).
The main function of C4bp is to inhibit classical pathway activation by preventing
formation of the C3 convertase C4bC2a (Scharfstein et al., 1978). To some extent, C4bp
also inhibits the alternative pathway, acting as a factor I cofactor in C3b cleavage (Seya et
al., 1995). The majority of C4bp is composed of seven -chains and a single -chain that
is responsible for binding of the anticoagulant protein S (Hillarp and Dahlback, 1988). In
the -chains, C4bp has a binding site for heparin (Hessing et al., 1990). Protein S is a 75-
II Review of the literature
45
kDa glycoprotein synthesized mainly by hepatocytes, but also by endothelium and
vascular smooth muscle cells (DiScipio and Davie, 1979; Fair and Marlar, 1986;
Dahlback, 1991). The C4bp-unbound fraction of protein S (40%) acts as a cofactor for the
activated anticoagulant protein C (Rezende et al., 2004).
In human tissue homeostasis, C4bp has an important role in limiting complement
activation on apoptotic cells to prevent the formation of anaphylatoxins and MAC (Blom
et al., 2004; Rezende et al., 2004). Whereas apoptotic cells are capable of binding several
complement components to potentially induce complement activation (Nauta et al., 2002),
C4bp binds via protein S to negatively charged phosphatidylserine to inhibit further
complement activation. C4bp is also able to bind CD40 and induce cell proliferation and
upregulation of ICAM-1 in B-cells (Brodeur et al., 2003). However, in addition to B-cells,
CD40 is also expressed on monocytes, dendritic cells, and endothelial cells (Blom et al.,
2004). In atherosclerotic plaques, C4bp is present in the proteoglycan-rich superficial
intima, where it probably binds to arterial proteoglycans (Oksjoki et al., 2007). In some
specimens, C4bp is only seen deeper in the intima and in the necrotic cores of advanced
lesions. A fraction of C4bp is associated with protein S and caspase-3 -positive apoptotic
cells.
Factor H and FHL-1
Together with C4bp, factor H (fH) is the most important soluble complement inhibitor. Its
main function is to inhibit the alternative pathway. Factor H is a single polypeptide chain
glycoprotein (155 kDa) found in plasma in varying concentrations (110-615 g/ml)
(Rodriguez de Cordoba et al., 2004). In addition to factor H, there are also at least six
structurally related proteins such as factor H-like protein 1 (FHL-1), an alternative
transcript of the factor H-coding gene cfh (Estaller et al., 1991; Rodriguez de Cordoba et
al., 2004).
Factor H inhibits the alternative pathway by accelerating the decay of the
alternative pathway C3 convertase (C3bBb) and acting as a cofactor for factor I to
inactivate C3b. Factor H is able to act both in solution and on surface-bound C3b. In
addition to several binding sites for C3b and iC3b, factor H also binds to sialic acids,
glycosaminoglycans, and sulfated polysaccharides such as heparin (Rodriguez de Cordoba
et al., 2004). By binding to CRP, factor H may limit alternative pathway amplification on
otherwise proinflammatory surfaces (Jarva et al., 1999). Factor H and FHL-1 are mainly
synthesized in the liver, although extrahepatic synthesis also occurs by, for example,
lymphocytes, fibroblasts, and endothelial cells (Friese et al., 1999). The proinflammatory
cytokine IFN-  seems to upregulate the synthesis of factor H and FHL-1 (Ripoche et al.,
1988; Rodriguez de Cordoba et al., 2004). In atherosclerotic arteries, factor H is present in
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the superficial layer of the intima, colocalizing with CRP and arterial proteoglycans, and
restricting terminal pathway complement activation in that area (Oksjoki et al., 2003a).
Several known mutations exist in the factor H gene. These are associated with, for
instance, type II membranoproliferative glomerulonephritis or aHUS (atypical hemolytic
uremic syndrome), where a deficient protection of host cells exposes them to complement
activation (Rodriguez de Cordoba et al., 2004). Factor H single-nucleotide polymorphism
Y402H was found in 2005 to be associated with age-related macular degeneration (AMD)
(Edwards et al., 2005; Haines et al., 2005; Klein et al., 2005). AMD is featured by
impaired clearance of debris and accumulation of drusen in the subretinal space.
Properdin
Properdin is synthesized by monocytes/macrophages, T-cells, neutrophils, and mast cells
(Schwaeble et al., 1993; Schwaeble et al., 1994; Wirthmueller et al., 1997; Stover et al.,
2008) at the site of inflammation upon stimulation (Wirthmueller et al., 1997). It is found
only in small concentrations (4-6 g/ml) in plasma (Nolan and Reid, 1993), where it
enhances activation of the alternative complement pathway. Properdin is a highly
positively charged (pI>9.5) protein (Fearon and Austen, 1975) and it binds heparin, a
major glycosaminoglycan (Yu et al., 2005). Properdin is secreted by leukocytes and
endothelial cells and is capable of leukocyte activation (Bongrazio et al., 2003; Ruef et al.,
2008). Properdin has traditionally been thought to stabilize only the C3bBb complex
attached to nonself surfaces (e.g. bacterial capsules) for more efficient alternative pathway
activation (Fearon and Austen, 1975). However, recent studies of early apoptotic T-cells
and late apoptotic Jurkat cells suggest that properdin itself is capable of danger target
recognition and launching subsequent alternative pathway activation (Kemper et al., 2008;
Xu et al., 2008). In the case of apoptotic T-cells, the sulfated glycosaminoglycans are a
prerequisite for properdin interaction. In atherosclerotic coronary arteries, properdin is
associated with the C5b-9 complex, and thus, indicates complement activation through the
alternative pathway (Oksjoki et al., 2007).
S-protein/Vitronectin
Vitronectin or S-protein is a glycoprotein (75 kDa) synthesized mainly by the liver and
present in plasma and serum at concentrations of 200-400 g/ml (Podack and Muller-
Eberhard, 1979; Barnes and Silnutzer, 1983; Ekmekci and Ekmekci, 2006). It is also
present in several tissues as a component of loose ECM and on the cell surface of, for
instance, fibroblasts (Hayman et al., 1983; Dahlback et al., 1986). It binds to the C5b-7
complex, preventing its insertion into the cell membrane. The SC5b-7 complex remains
hydrophilic and is thus soluble (Bhakdi and Roth, 1981). Vitronectin also prevents the
polymerization of C9, inhibiting the formation of the tubular structure of MAC (Podack et
al., 1984). In addition, vitronectin binds to plasminogen activator inhibitor-1 (PAI-1),
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thrombin-antithrombin III complexes, heparin, and probably also collagen type I. It has
been suggested to have functions in cell adhesion, migration, vascular remodeling,
thrombosis, hemostasis, fibrinolysis, and immune defense (reviewed by Ekmekci and
Ekmekci, 2006). In human atherosclerotic arteries, vitronectin has been found to partially
colocalize with C5b-9, especially in intimal fatty streaks, intimal thickenings, and fibrous
plaques as well as in the ECM and cell debris (Niculescu et al., 1987). Vitronectin was
associated with C5b-9, particularly in cell debris embedded in elastin, whereas cell debris
embedded in collagen was positive only for C5b-9 (Niculescu et al., 1989). Recently,
vitronectin was observed to be one of the seven differently expressed proteins in
unruptured and ruptured abdominal aortic aneurysms (AAAs) (Urbonavicius et al., 2009).
Its downregulation was associated with AAA rupture.
Protectin
Protectin or CD59 is a small (~20 kDa) glycophosphatidylinositol (GPI)-anchored
glycoprotein that is widely expressed on cell membranes of almost all circulating cells and
tissues in the body (Meri et al., 1991). It belongs to the leukocyte antigen 6 (Ly-6) protein
superfamily (Davies et al., 1989). Protectin inhibits MAC formation by preventing the
binding of C9 to the C5b-8 complex (Rollins and Sims, 1990; Meri et al., 1991; Farkas et
al., 2002). In addition to complement inhibition, protectin contributes to T-cell signaling
and autoregulation (Longhi et al., 2006; Kimberley et al., 2007) as well as to B-cell
signaling (Kimberley et al., 2007). In human keratinocytes, protectin acts as an LPS
receptor, instead of CD14, leading to NF B–mediated production of granulocyte-
macrophage colony-stimulating factor, IL-6, and TNF-  (Yamamoto et al., 2003).
Protectin is essential for viable cells to survive complement lysis, as patients with
paroxysmal nocturnal hemoglobinuria (PNM) suffer from hemolytic anemia due to an
acquired lack of GPI-anchored proteins or inherited deficiency of protectin on erythrocyte
cell membranes (Yamashina et al., 1990; Parker, 1991; Motoyama et al., 1992). Patients
with PNM have a small tendency to develop vascular thrombosis. In atherosclerotic
arteries, protectin has been seen on macrophages, T-cells, endothelial cells, and SMCs,
partially overlapping with the C5b-9 complex (Seifert et al., 1992; Yasojima et al.,
2001a). Extensive glycosylation may inactivate protectin and is a mechanism postulated to
be responsible for diabetic vascular complications (Acosta et al., 2000; Qin et al., 2004).
CR1
Complement receptor 1 (CR1), or CD35, is a membranous receptor for C1q (Klickstein et
al., 1997), MBL (Ghiran et al., 2000), C3b, and C4b (Klickstein et al., 1988). It has
cofactor activity for factor I in cleaving C3b and C4b (Ross et al., 1982). By binding to
C3b/C4b, CR1 destabilizes and enhances the decay of C3/C5 convertases, thereby
inhibiting complement activation (Khera and Das, 2009). CR1 is expressed on the plasma
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membrane of several cell types, including erythrocytes, monocytes, macrophages, B-
lymphocytes, a subpopulation of CD4+ T-cells, and dendritic cells (Khera and Das, 2009).
CR1 also circulates in plasma in a soluble form (sCR1) generated by proteolytic cleavage
of the leukocyte surface-bound CR1 (Hamer et al., 1998). Being expressed on all blood
cells, CR1 aids in the transport of C3b/C4b-coated immune complexes to the liver and
spleen.
Decay-accelerating factor
Decay-accelerating factor (DAF), or CD55, is a 75-kDa GPI-anchored protein expressed
on the cell membranes of most plasma-exposed cells (Nicholson-Weller et al., 1985).
Many bacteria and viruses use DAF as a receptor for adhesion and often also for invasion
(reviewed by Lea, 2002). DAF inhibits complement activation by dissociating the catalytic
subunits C2a and Bb of the classical pathway and alternative pathway target enzymes
C4b2a and C3bBb, respectively (Brodbeck et al., 2000). In malignancies, DAF increases
the invasiveness by protecting the tumor from complement and apoptosis as well as by
inducing neoangiogenesis (Mikesch et al., 2006). DAF is also expressed in atherosclerotic
lesions. The expression is mainly extracellular, although a variable proportion of cells (20-
60%) also express DAF (Seifert and Hansson, 1989a). DAF is the most inducible of the
complement membrane regulators on endothelial cells (Meri et al., 1993).
Membrane cofactor protein
Membrane cofactor protein (MCP), or CD46, is a 60- to 65-kDa complement inhibitor
expressed widely on cells throughout the body, except erythrocytes (Liszewski et al.,
1991). MCP is associated with the plasma membrane via its C-terminal transmembrane
domains. In addition to the membrane-bound form, MCP can be released from cancer cells
with an MMP as a soluble form and with an analogous complement inhibitory capacity as
the membrane-bound form (Hakulinen et al., 2004). MCP binds to C3b and C4b deposited
on the cell surface and acts as a cofactor for plasma serine protease factor I to promote the
generation of iC3b and iC4b (Liszewski et al., 1991). MCP may transduce cellular
signaling, as MCP can downregulate IL-12 secretion on monocytes and affect T-cell
cytotoxicity, proliferation of helper T-cells, and production of IL-2 and IL-10 (Karp et al.,
1996; Marie et al., 2002).
2.3.3 Role of complement in clearance of cellular debris
Growing evidence points to the role of complement in the clearance of cellular debris.
Apoptotic cells are highly immunogenic and proinflammatory if not promptly cleared
(Chang et al., 2004). This is due to mitochondrial disruption, leading to oxidation of
various epitopes expressed on apoptotic blebs (Chang et al., 1999; Huber et al., 2002).
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During early apoptosis negatively charged phosphatidylserine is transferred to the outer
cell membrane leaflet. It is thought to be responsible for binding of complement
components and natural IgM antibodies. Apoptotic cells also downregulate complement
inhibitors (Attali et al., 2004), exposing the cells to complement activation and
complement-mediated necrosis. Apoptotic cells bind several complement components,
most importantly C1q (Nauta et al., 2002). In addition, other complement activators (e.g.
pentraxins CRP and PTX-3, IgM, and IgG), MBL, and ficolins bind to apoptotic cells and
activate complement to enhance phagocytosis of apoptotic bodies. The alternative
pathway also plays a role in priming apoptotic cells for phagocytes, as bound Bb is seen
especially prominently on apoptotic/necrotic cells (reviewed by Trouw et al., 2008).
However, in addition to complement components, complement inhibitors also bind to
apoptotic cells; C4bp binds to the blebs of apoptotic cells via protein S to prevent
complement activation and formation of anaphylatoxins and MAC (Blom et al., 2004).
The binding of both complement activators and inhibitors by apoptotic cells is believed to
orchestrate organized removal of apoptotic cells with a minimum inflammatory response
(Trouw et al., 2008). The binding of complement components to other tissue structures
may serve a similar function.
2.3.4 Role of terminal complement activation in cell fate
If not inhibited, the terminal complement pathway leads to the assembly of MACs on
target cell membranes. When assembled in massive amounts, the transmembrane pores of
MACs result in the free passage of solutes and water through the membrane. This leads to
lysis of the target and to a proinflammatory, necrotic cell death (Bhakdi and Tranum-
Jensen, 1991). Necrotic cells also rapidly lose their membrane inhibitors DAF, MCP, and
protectin, promoting further complement activation (Trouw et al., 2008). However, if the
amounts of MAC remain sublytic, the cells may escape lysis by internalization of the
MACs by endocytosis and membrane shedding (Carney et al., 1985; Scolding et al.,
1989). However, sublytic amounts of MAC have been noted to increase Ca2+ influx,
activate phospholipases and protein kinase C, generate arachidonic acid-derived
inflammatory mediators, induce proto-oncogenes, activate the cell cycle, and inhibit
apoptosis (reviewed in Rus et al., 2001). In human aortic SMCs, sublytic MAC promotes
the cell cycle, resulting in cell division by the activation of ERK-1 (extracellular signal-
regulated kinase 1) of the MAPK pathway (Niculescu et al., 1999). This will enhance cell
survival and induce resistance to a subsequent MAC attack. Importantly, in addition to cell
protection, sublytic MAC is also capable of inducing apoptosis through a caspase-3-
dependent pathway (Nauta et al., 2002). As MAC has both proapoptotic and antiapoptotic
effects, the final cell fate is probably affected by the extracellular environment, e.g. by
cytokines.
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2.3.5 Complement system and coagulation
In large tissue traumas, activation of both the complement and coagulation cascades is
evident. Moreover, the complement C1 esterase inhibitor (C1-INH) has long been known
to inhibit the coagulation cascade and kinin enzymes (FXIIa and kallikrein). However,
recent studies have revealed more versatile interactions of the complement and
coagulation cascades (Amara et al., 2008). In addition to the cofactor activity of C4bp-free
protein S on activated protein C in the anticoagulant pathway (Rezende et al., 2004), C5a
may activate the exogenous coagulation pathway by inducing tissue factor (TF) activity in
endothelial cells (Ikeda et al., 1997; Amara et al., 2008). Coagulation factors may also be
responsible for complement activation and especially for the generation of anaphylatoxins,
particularly since thrombin is capable of acting as a potent C5 convertase (Huber-Lang et
al., 2006). The coagulation factors FXa and FXIa, generated during activation of the
intrinsic coagulation cascade, are also capable of cleaving C3 and C5 (Amara et al., 2008).
Finally, plasmin, the strongest serine protease of the fibrinolytic system, is capable of
cleaving both C3 and C5 (Amara et al., 2008).
2.4 Complement in the vascular wall
Complement activation has been studied in only selected arterial diseases and in some
disease states that also have an effect on arteries. As IAs are dilatations of middle-sized,
musculoelastic arteries, a special emphasis is placed on reviewing complement activation
in atherosclerotic arterial remodeling and aneurysms as well as on the role of complement
in arterial injury caused by ischemia-reperfusion (I/R).
2.4.1 Complement in normal arteries
Normal arterial wall is protected from complement by membrane-bound inhibitors MCP,
DAF, and protectin, which are ubiquitously expressed on most nucleated cells (Seifert and
Hansson, 1989a; Liszewski et al., 1991; Meri et al., 1991; Seifert et al., 1992). C4bp
(Oksjoki et al., 2007) and factor H have been detected diffusely in the proteoglycan-rich
areas of the intima and media of arterial walls (Oksjoki et al., 2003a). No studies of the
presence of complement regulators in normal cerebral arteries are available. Of the
complement components, C3 has been detected occasionally in normal basilar arteries. C9
has been absent or occasionally present as a diffuse staining pattern in normal basilar
arteries (Chyatte et al., 1999). In normal coronary arteries, no staining for C3d, or C5b-9
has been observed (Oksjoki et al., 2003a). Of potential complement activators, IgG has
not been detected in normal basilar arteries, and IgM has been detected only occasionally
as a diffuse staining pattern in normal basilar arteries (Chyatte et al., 1999). In coronary
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arteries, CRP was seen only in the superficial intima together with factor H (Oksjoki et al.,
2003a).
Although the majority of the complement components are produced in the liver,
there is also some extrahepatic, local production of complement components, especially
during inflammation (Laufer et al., 2001). The local production of complement
components is regulated by several cytokines, e.g. IL-1, IL-2, IL-6, IL-13, IL-17, TNF- ,
and IFN- , and growth factors PDGF, EGF, FGF, and TGF- 1 (reviewed in Laufer et al.,
2001). Endothelial cells are capable of synthesizing C3, C5-9, and factor H, and
fibroblasts produce C2, C3, and C5-9 (Andrews et al., 1995). Smooth muscle cells
synthesize at least C3 and C4 (Ueda et al., 1996; Yasojima et al., 2001b). In addition,
platelets and inflammatory cells, monocytes, macrophages, T-cells, and
polymorphonuclear leukocytes are capable of producing complement components (C1q, r,
s, C2, C4, C3), regulators (C1-INH, C4bp, fH, factor I, properdin, factor B, factor D), and
several receptors for complement components (C1qR, CR1, CR2, CR3, CR4, C3aR,
C5aR) (Andrews et al., 1995; Morgan and Gasque, 1997).
2.4.2 Complement in vascular diseases
Aneurysms
Two recent microarray analyses have shown a differential expression of complement-
related genes in IAs compared with control arterial tissue (Krischek et al., 2008; Shi et al.,
2009). In immunostainings, Chyatte et al. (1999) found complement components C3 and
C9 in mostly unruptured IAs and suggested that the complement system is activated in
IAs. They also detected IA-associated IgG and IgM, which are known to activate
complement. Earlier, Ryba et al. (1992) had reported accumulation of IgM and/or C3 on
the luminal surface of IAs after aSAH. In AAAs, the amounts of IgG subtypes, measured
from tissue extraction, are enormously increased: IgG1 (193-fold), IgG2 (160-fold), IgG3
(389-fold), and IgG4 (627-fold) compared with a normal aortic wall. The presence of
several C3 degradation products has also been noted in AAAs (Capella et al., 1996).
Vasospasm
Delayed vasospasm following aSAH is manifested by smooth muscle cell contraction,
which is probably secondary to an inflammatory reaction (Pluta et al., 2009). Plasma C3d
and C4 levels of aSAH patients increase at the time of vasospasm, but remain normal in
aSAH patients without vasospasm (Ostergaard et al., 1987a; Kawano and Yonekawa,
1990). Complement activation may have a role in the induction of a delayed vasospasm
following aSAH. In experimental models, artificial particles alone (latex and dextran) can
activate complement (Carreno et al., 1988; Luck et al., 1999) and induce vasospasm
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(Peterson et al., 1990; Yanamoto et al., 1994). The complement system has an inherent
activity to recognize foreign surfaces and become activated. The complement activation
products, anaphylatoxins (C3a, C4a, C5a), are chemotactic to inflammatory cells. They are
also able to induce the endothelial expression of cell adhesion molecules VCAM-1,
ICAM-1, and selectins (Foreman et al., 1996; Albrecht et al., 2004; DiScipio and
Schraufstatter, 2007). The complement system has been found to become activated in the
cerebrospinal fluid after SAH. Levels of the terminal complement complex are highest
during the first two days after SAH, decreasing to the level of plasma concentrations in 7-
10 days (Lindsberg et al., 1996). Complement depletion inhibits vasospasm in
experimental models of cerebral vasospasm (German et al., 1996).
Atherosclerosis
In extracranial arteries, atherosclerotic lesions develop as progressive thickening of the
intima and lipid accumulation within the plaque. The IEL remains intact and probably
protects the media from the pathologic changes. Complement activation has been detected
in atherosclerotic arteries, and it is widely accepted as a potential pathogenetic mechanism
in the progression of atherosclerosis. Complement activation has even been suggested as
an initiating event of the atherosclerotic changes because C5b-9 has been found to
accumulate in the intima with lipids and to precede inflammatory cell infiltrations and
other atherosclerotic changes in an experimental model in rabbits (Seifert et al., 1989).
Both early complement components C1q, iC3b, C3d, C4, and C4c and components of the
terminal pathway (C9 and C5b-9) have been detected in atherosclerotic arteries (Vlaicu et
al., 1985b; Seifert et al., 1989; Oksjoki et al., 2003a; Oksjoki et al., 2007).
The intensity of C5b-9 deposition has been correlated with the disease state
(Vlaicu et al., 1985a). The heaviest deposition of C5b-9 by immunohistochemistry has
been seen in fibrous plaques, suggesting a pathogenetic involvement of complement in
chronic progression of the lesions (Vlaicu et al., 1985a). C5b-9 accumulation has occurred
especially in the deeper musculoelastic layer of the intima, whereas the superficial,
proteoglycan-rich layer is protected from terminal complement activation by C4bp and
factor H, which have been shown to bind to the arterial proteoglycans (Oksjoki et al.,
2003a). In IEL, C5b-9 has been localized particularly on apoptotic cells and cellular debris
(Rus et al., 1986). Atherosclerotic arteries also harbor IgG, IgM, and IgA (Vlaicu et al.,
1985a; Oksjoki et al., 2007).
IgM class NAbs (Chou et al., 2009) have been suggested to have a role in the
induction of complement classical pathway activation in myocardial infarction (Zhang et
al., 2006). NAbs may also have a protective role in atherosclerosis, as they recognize the
proinflammatory oxidative epitopes that could reduce the scavenger-receptor-mediated
uptake of oxLDL by macrophages and thereby decrease atherosclerosis (Hartvigsen et al.,
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2009; Lewis et al., 2009). In atherosclerosis, the complement system has been proposed to
become activated through the classical pathway (Yasojima et al., 2001a; Oksjoki et al.,
2003a), but evidence has also emerged in support of purely alternative pathway-mediated
complement activation by the colocalization of properdin and C5b-9 (Oksjoki et al.,
2007).
Ischemia-reperfusion injury
Ischemia-reperfusion (I/R) injury occurs as a response to reperfusion in a tissue that has
sustained ischemia because of a depletion in oxygen supply due to insufficient blood
circulation. Reperfusion leads to the generation of immunogenic reactive oxygen species,
release of cytokines, and expression of adhesion molecules. The restored circulation
imports immune reactants (e.g. immunoglobulins, acute phase proteins, leukocytes) that
recognize ischemia-injured tissue elements and activate innate immune responses. These
may lead to an advanced inflammatory reaction and tissue damage within hours (reviewed
by Fleming, 2006; Diepenhorst et al., 2009). Both IgM and IgG class natural antibodies in
association with neutrophils and complement play a role in inducing the injury (Hernandez
et al., 1987; Williams et al., 1999; Fleming et al., 2002). Complement activation has been
accompanied by the loss of the complement inhibitor protectin, e.g. in acute myocardial
infarction (Väkevä et al., 1992). In experimental studies, the complement system has been
found to play a key role in mediating the injury (Hill and Ward, 1971). In a rat model of
brain infarction, an inhibition of all complement pathways by C1-INH protected the brain
from I/R injury (Akita et al., 2003; De Simoni et al., 2004). In I/R injury, both the
classical and the lectin complement pathways are involved initially via the recognition of
exposed neo-epitopes in the ischemic tissue. Subsequently, complement activation is
amplified by the alternative pathway (Fleming, 2006; Diepenhorst et al., 2009).
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III AIMS OF THE STUDY
Complement activation seems to play a key role in many chronic inflammatory diseases,
including arterial diseases. However, practically very little is known about the possible
role of complement activation in IA wall pathobiology and its relation to IA wall
degeneration and rupture.
The objectives of this study were the following:
1. To investigate whether complement activation has occurred in unruptured or ruptured
IAs and whether it is associated with IA wall degeneration and inflammatory cell
infiltrations.
2. To identify complement activation pathways in unruptured and ruptured IAs and to
determine whether complement activators are present in the IA wall.
3. To evaluate the complement regulatory mechanisms in the IA wall.
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IV PATIENTS AND METHODS
1 Patients and samples
The samples of IA fundi distal to the aneurysm clip were resected during microsurgery at
the Department of Neurosurgery, Helsinki University Central Hospital. The specimens
were immediately snap-frozen in liquid nitrogen or fixed for electron microscopy. The
snap-frozen samples were stored at -80 C. Clinical data and demographics were collected
from medical records (patient age, gender, multiplicity of IAs, previous SAHs, smoking,
alcohol abuse, hypertension, and family history). IA dimensions (fundus lengths, fundus
width, and neck width) were obtained from the preoperative vascular imaging studies
(computed tomographic angiography, magnetic resonance angiography, or digital
subtraction angiography). The venous whole blood samples were drawn postoperatively.
The study protocol was approved by the local Ethics Committee (Departments of
Neurology, Neurosurgery, Ophthalmology, and Otorhinolaryngology, Helsinki University
Central Hospital). A total of 162 patients were included in the study, 43 of whom had
previously been histologically characterized (Frösen et al., 2004).
2 Histological studies (I-III)
For histological studies, the snap-frozen tissue specimens were embedded in OCT Tissue
Tek compound (Sakura, Torrance, CA, USA) and cryosectioned at 4 m.
2.1 Histological stainings (I-III)
For basic morphological analysis, the sections were stained with Mayer’s hematoxylin and
eosin G.
The neutral lipids were stained with Oil-Red-O in unfixed cryosections. The
sections were incubated in absolute propylene glycol (Sigma-Aldrich, St. Louis, MO,
USA) for 5 min, followed by incubation in 0.5% Oil-Red-O solution in propylene glycol
for 7 min, and then washed twice in 85% propylene glycol, running tap water, and aqua.
The nuclei were background-stained with Mayer’s hematoxylin.
For staining of sulfated glycosaminoglycans, the cryosections were fixed in ice-
cold acetone for 2 min, rinsed in running tap water, incubated in 1% Alcian Blue in 3%
acetic acid at pH 2.5 for 3 min, rinsed in running tap water, and mounted in an aqueous
mounting medium (VWR International Ltd., Poole, England).
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2.2 Immunohistochemistry and immunofluorescence stainings
(I-III)
Antibodies
The names, sources, and dilutions of primary antibodies used in the immunohistochemical
and immunofluorescence stainings are listed in Table 1. The functions of their target
antigens in complement activation and regulation are briefly described in Table 2.










C1q anti-C1q Rabbit pAb 1:1000 DAKO Lipoproteins II
C3c anti-C3c Rabbit pAb 1:1000 DAKO - II
C3d 4C2 Mouse mAb 1:100 (Koistinen et
al., 1989)
- II
C4c anti-C4c Rabbit pAb 1:400 DAKO - II
SC5b-9
(TCC)








Properdin  anti-properdin Goat pAb 1:400 INCSTAR TCC II
Factor H anti-factor H Goat pAb 1:400 Calbiochem TCC III
C4bp anti-C4bp Rabbit pAb 1:1000 (Hallstrom et
al., 2007)
- III
Protein S anti-protein S Rabbit pAb 1:400 Sigma1 - III
Protectin
(CD59)
BRIC 229 Mouse mAb 1:200 IBGRL - I, III
Complement activators
CRP anti-CRP Goat pAb 1:200 Kallestad TCC II
IgG anti-IgG (FITC) Rabbit pAb 1:50 Sigma2 TCC II
IgM anti-IgM (FITC) Rabbit pAb 1:50 Sigma2 TCC II
ApoB-100 MB47 Mouse mAb 1:500 (Young et
al., 1986)
C1q II
mmLDL Ox4E6 Mouse mAb 1:200 (Holvoet et
al., 1996)
C1q II
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Other
Ki67 MIB-1 Mouse mAb 1:250 DAKO TCC I
SMA 1A4
(Cy3)
Mouse mAb 1:1000 Sigma2 TCC I, II
C4bp, C4b binding protein; CRP, C-reactive protein; IgG, immunoglobulin G; IgM, immunoglobulin
M; mmLDL, minimally modified low-density lipoprotein; HNE, hydroxynonenal; SMA, alpha
smooth muscle actin; FITC, fluorescein isothiocyanate; Cy3, Cyanine Dye 3; pAb, polyclonal
antibody; mAb, monoclonal antibody; fH, factor H; DAKO, DakoCytomation, Glostrup, Denmark;
Quidel, Quidel Corporation, San Diego, CA, USA; INCSTAR Corporation, Stillwater, MN, USA;
Calbiochem, EMD Chemicals Inc., Darmstadt, Germany; Sigma1, Sigma Bio Sciences, St. Louis,
MO, USA; IBGRL, International Blood Group Reference Laboratory, Bristol, UK; Kallestad,
Chaska, MI, USA; Sigma2, Sigma-Aldrich, St. Louis, MO, USA
Table 2. Primary antibody targets and their functions in complement activation.
Antigen (staining for) Role
Complement C1q CP component
Complement C3c (C3b/iC3b) AP components
Complement C3d AP component
Complement C4c (C4b/iC4b) CP components
Complement SC5b-9 (C5b-9) Terminal complement complex
Properdin C3bBb stabilizer; AP amplification
Factor H Soluble decay accelerator of C3bBb; AP inhibition
C4b binding protein Soluble decay accelerator of C4b2a; CP inhibition
Protein S Anticoagulant protein; in complex with C4b binding protein
Protectin / CD59 Membrane-bound C5b-9 inhibitor;
inhibition of membrane attack complex
C-reactive protein CP activation
Immunoglobulin G CP activation
Immunoglobulin M CP activation
ApoB-100 Main LDL protein; potential CP activator
Minimally modified LDL Oxidized LDL; potential CP activator
Hydroxynonenal Oxidized LDL; potential CP activator
Ki67 Proliferation marker; potentially induced by C5b-9
Alpha smooth muscle actin Smooth muscle cell cytoskeletal protein; potential target cell
CP, complement classical pathway; AP, complement alternative pathway; LDL, low-density
lipoprotein
Immunohistochemistry
The tissue sections were fixed with 4% paraformaldehyde, and nonspecific binding was
blocked with 1% bovine serum albumin (BSA; Sigma-Aldrich Inc., St. Louis, MO, USA)
or 3-5% normal goat or horse serum (Vector Laboratories Inc., Burlingame, CA, USA) in
phosphate-buffered saline (PBS). Some sections were additionally blocked with 0.5% cold
fish skin gelatin (Sigma) in PBS containing 0.5% BSA (BSA/PBS). The primary
antibodies were diluted in 1% BSA/PBS and incubated for 30 min at room temperature or
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overnight at 4 C. The endogenous peroxidase was blocked with 0.3-0.7% hydrogen
peroxide in PBS or methanol. The sections were incubated with biotinylated secondary
antibodies (Vector) for 30 min at room temperature. The signal was enhanced by
horseradish peroxidase or alkaline phosphatase-conjugated avidin-biotin complexes and
visualized with diaminobenzidine (Sigma) or Vector Blue (Vector), respectively. The
background was stained with Mayer’s hematoxylin or Carmaleum.
Immunofluorescence stainings
For immunofluorescence stainings, the fixation, blocking, and incubation with the primary
antibody were performed as described above. The primary antibody (Table 1), if
unconjugated, was detected with fluorochrome-conjugated Alexa Fluor 488 (green) or 546
(red) secondary antibody (Molecular Probes Inc., Eugene, OR, USA) diluted to 1:100-
1:200. For double-immunofluorescence stainings, the incubations were repeated with
antibodies originating from different species. The slides were mounted in Vectashield with
DAPI (Vector) to detect the nuclei.
Controls
Human tonsils and infarcted heart served as the positive controls for the stainings. For
negative controls, the primary antibody was omitted or replaced with an irrelevant
antibody of the same immunoglobulin isotype as the primary antibody.
2.3 TUNEL assay (I)
TUNEL (terminal deoxynucleotidyl transferase (dUTP) nick end labeling) assay was used
to detect apoptotic cells. For immunofluorescence and TUNEL double stainings, an
additional TUNEL reaction was performed using a Fluorescein In Situ Cell Death
Detection kit (Roche Diagnostics GmbH, Penzberg, Germany) following the
immunofluorescence staining (Kitagawa et al., 1998).
2.4 Electron microscopy and immunoelectron microscopy (I)
The IA sample was immersion-fixed in 4% paraformaldehyde (Electron Microscopy
Sciences, Fort Washington, PA, USA). For the morphological analysis, specimens were
further fixed in 2.5% glutaraldehyde (Fluka, Buchs, Switzerland), postfixed with 1%
osmium tetroxide, dehydrated, and embedded in Epon (TAAB Laboratories Equipment
Ltd., Berkshire, England). The diluent was 100 mmol/L natrium phosphate buffer, pH 7.4.
For immunoelectron microscopy (IEM), paraformaldehyde-only-fixed specimens were
low-temperature-embedded into Lowicryl (HM20; TAAB Laboratories Equipment Ltd.).
Dehydration, resin infiltration, and ultraviolet polymerization were performed at -30°C.
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The ultrathin sections (60 nm) were blocked with 1% BSA, 0.5% cold fish skin gelatin
(Sigma), and 1% heat-inactivated fetal calf serum (BioWhittaker, Walkersville, MD). The
primary antibody (A239) was detected with goat anti-mouse IgG and IgM conjugated with
10 nm colloidal gold (British Biocell, Cardiff, England). Both antibodies were diluted with
2% BSA, 0.1% Tween 20 (Electron Microscopy Sciences), and 0.1% cold fish skin
gelatin. All specimens were poststained with uranyl acetate (Ultrostain I; Leica, Wetzlar,
Germany), lead citrate (Ultrostain II; Leica).
2.5 Imaging
The immunohistochemical stainings were photomicrographed with an Axioplan 2 imaging
microscope and AxioCam MRc (Carl Zeiss Vision GmbH, Aalen, Germany). The
immunofluorescence stainings were viewed and photographed with Axioplan 2 and
AxioCam (HR/MR) cameras, with appropriate filters to create pseudocolored images
(Zeiss). The electron microscopy was performed with a Jeol EX 1200 II transmission
electron microscope (Jeol Ltd., Tokyo, Japan) operating at 60 kV.
2.6 Histological evaluation
For semiquantitative and quantitative histological evaluations, the measurements were
performed up to three times, and the mean values were used for calculating correlations or
for comparisons.
Evaluation of MAC-positive areas (I)
The following two kinds of measurements of MAC-positive areas were performed from
immunoperoxidase-stained histological samples with the KS300 3.0 image processing
software (Carl Zeiss GmbH, Oberkochen, Germany): 1) The percentage of the MAC-
positive area of the total surface area of one section of each histological sample was
measured under x1.25 magnification. The mean values were used to correlate the area of
complement activation with IA rupture status with the patient’s clinical parameters, IA
rupture status, histological markers, and inflammatory cell infiltrations. 2) The
percentages of the MAC-positive areas of the areas representing specific wall types were
measured under x5 magnification. The areas were classified on the basis of the previously
published grading system of four different histological, rupture-related IA wall types: (A)
an endothelialized wall with linearly organized smooth muscle cells; (B) a thickened wall
with disorganized smooth muscle cells; (C) a hypocellular wall with either myointimal
hyperplasia or organized thrombus; and (D) an extremely thin thrombosis-lined
hypocellular wall (Frösen et al., 2004).
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Evaluation of cellular infiltrations (I)
The histological data for inflammatory cell infiltrations of the 43 previously studied IAs
had been published by Frösen et al. (2004). The inflammatory cell infiltrations were
quantified as the number of positive cells, and the proliferation was quantified as the
proportion of Ki67-positive nuclei per standardized grid area (0.0625 mm2). The presence
or absence of proliferating cells, endothelial cells, remnants of elastic lamina,
atherosclerotic calcifications, myointimal hyperplasia, and thrombosis lining the lumen
was categorically scored (yes/no). The proportion of TUNEL-positive cells was quantified
per field of view (0.0956 mm2) and the colocalization of positive staining for MAC and
positive TUNEL reaction was evaluated.
Evaluation of complement components (II)
Antigen deposition in the IA wall was classified as mild, moderate, or strong depending
on the extent of the positively staining areas relative to the whole IA wall surface area
(mild <1/3, moderate 1/3-2/3, strong >2/3). The presence or absence of complement
components was screened in the areas of interest within parallel sections.
Evaluation of complement activators (II) and inhibitors (III)
Single- and double-stained IAs were screened for the location of the positive staining
within cells or the extracellular matrix. The localizations of the antigens were compared
with each other in serial sections.
3 Analysis of single-nucleotide polymorphisms (III)
DNA was extracted from blood mononuclear cells by the ethanol precipitation method
(Gentra Puregene Genomic DNA Purification Kit, Gentra Systems, Minneapolis, MN,
USA). The region corresponding to the Y402H polymorphic site of the cfh gene was
amplified by PCR and sequenced using the forward primer 5'-ctttgttagtaactttagttcg-3' and
the reverse primer 5’-ttagaaagacatgaacatgctagg-3’. PCR amplifications were performed in
50-µl volumes containing 80 ng of genomic DNA, 30 pM each primer, polymerase buffer,
10 nM each nucleotide (dNTP), and 0.8 U of the Dynazyme polymerase enzyme
(Finnzymes). Sequencing was performed using cycle sequencing with the Big Dye
Terminator kit (version 3.1; Applied Biosystems Inc., Foster City, CA, USA). The
reactions were run on an ABI 3730 capillary sequencer according to the manufacturer’s
instructions.
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4 Statistical analysis
For the statistical comparison of clinical and histological data on unruptured and ruptured
aneurysm samples, the proportions were calculated for patient gender, multiple IAs,
patients with prior aneurysmal SAHs, and binomially classified histological markers.
Means, medians, and ranges were calculated for patient age, IA dimensions, and
inflammatory cell infiltrations or proportions of TUNEL+ cells, and Chi-Square ( 2) and
Mann-Whitney U tests were used when appropriate. For comparison of the proportion of
MAC-positive area with clinical data and histological markers, Mann-Whitney U and
Spearman-Rank correlation tests were used. For calculating the correlation between IA
wall type and complement activation, the percentages of MAC-positive areas specific for
each wall type were converged to square roots to achieve normal distribution. The
differences were considered significant when the P-values were below 0.05.
A linear mixed model (LMM) was used to explore the association between the
percentage of areas positive for MAC in order to account for variation between
histological cuts with varying number of measurements. The LMM model (Laird and







Here, 1 is the square root of the percentage of areas positive for MAC in wall type
A adjusted for other effects, coefficients for fixed effects, and random effects. In all
models, 2, 3, and 4 are the regression coefficients for comparing three different IA wall
types: the proliferating type B (x2ij=1, if wall type B, 0 otherwise), the decellularized type
C (x3ij=1, if wall type C, 0 otherwise), and the thin, degenerated type D (x4ij=1, if wall
type B, 0 otherwise) with the intact-appearing type A. To allow cut-specific variation in




Basic univariate tests were obtained with NCSS 2000 (NCSS Statistical Software,
Kaysville, UT, USA) or SPSS 16.0 (SPSS, Chicago, IL, USA), and a linear mixed model
was fitted using R 2.1.0-A Language and Environment (public domain software) (R
Development Core Team, 2004).
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V RESULTS AND DISCUSSION
1 Complement activation in intracranial aneurysms
Complement becomes activated in the IA wall through the classical pathway with
amplification via the alternative pathway. By immunohistochemical and
immunofluorescence stainings, C1q was seen broadly in the IA wall and both C4b/iC4b
and C3b/iC3b overlapped with the band-like area of the terminal pathway activation and
C5b-9 formation at the less cellularized area at the outer part of the IA wall. The lack of
properdin in the same area contradicts an independent activation of the alternative
pathway. The luminal part of the IA wall is protected by fH and C4bp, possibly through an
interaction with glycosaminoglycans. Bound fH and C4bp did not appear to be sufficient
to prevent TCC activation in all IA areas because they partially overlapped with C5b-9 in
the outer part of the IA wall. The limiting inhibitor for full assembly of C5b-9 seems to be
protectin, which stained reciprocally to C5b-9. Complement may become activated by
many activators, as IgG, IgM, CRP, and oxLDL were scattered throughout the IA wall
without a reproducible pattern. However, neutral lipids seemed to colocalize with C5b-9,
suggesting their role in TCC activation (Figure 9).
1.1 Role of complement in intracranial aneurysm inflammation
and vascular damage
The most intense staining for TCC was located consistently as a distinct layer in the outer
IA wall. This area showed loss of nuclei, as fewer nuclei were present in this layer than in
the adjacent MAC-negative area in 28/35 samples (80%). Notably, this area would
represent the outer media of a healthy arterial wall. Electron microscopy (EM) analysis of
this area revealed dying cells featuring necrotic cell death as well as probable cell
remnants (I). Some additional TCC was found occasionally in patches of myointimal
hyperplasia, where cell nuclei were scattered normally in a majority of the samples (21/23;
91%). The relative proportion of TCC-positive areas within the samples varied (range 5-
77%), suggesting differences in the depth of inflammation in IAs. The relationships
between TCC activation, as a marker of complement activation intensity, and different
histological and clinical parameters are referred to and discussed in the following sections.
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Figure 9. Presence of complement components, regulators, and potential activators in the
intracranial aneurysm wall. The brackets represent the typical localizations of positive stainings
for the different complement (C) components studied in the immunohistochemical,
immunofluorescence, and histological stainings of the IA walls.
1.1.1 Association with aneurysm wall degeneration and rupture (I, II)
The terminal complement complex (TCC) or complement membrane attack complex
(MAC) was found in all studied IAs, totaling 26 unruptured and 32 ruptured IAs. The
proportion of TCC-positive area within the whole IA wall surface area was associated
with IA rupture (p=0.005; Mann-Whitney U test). The ruptured IAs showed wider relative
areas of terminal complement activation (median 39%; range 13-60%) than the unruptured
IAs (median 20%; range 5-77%) (I). In addition, the differences in the distribution of
earlier complement components (C1q, C3b/iC3b, C3d, and C4b/iC4b) between unruptured
and ruptured IAs were similar, as unruptured IAs showed less accumulation of all the
studied earlier components (p=0.011 for C1q, p=0.001 for C4b/iC4b, p<0.001 for
C3b/iC3b, p=0.048 for C3d; 2 test) (II). C5b-9 accumulation was located in subareas of
the earlier components. This indicates that in the TCC-negative areas, TCC formation was
inhibited, as was shown in Study III (Figure 9). The need for activation of the complement
system for TCC formation was suggested by the presence of earlier complement
components in the same areas. In atherosclerotic plaques, the magnitude of TCC
deposition has been associated with plaque degeneration (Vlaicu et al., 1985a) and
increased susceptibility to plaque rupture (Meuwissen et al., 2006). Thus, TCC activation
seems to be related to mechanisms that weaken the vascular wall, making it more prone to
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rupture. Whether the critical element is the complement activation itself or, for example, a
consequent leukocyte influx that leads to wall degeneration cannot be determined at this
point.
Further evidence for the association of complement activation and IA wall
degeneration was obtained from the evaluation of the median percentages of TCC-positive
areas within the different IA wall types (determined by Frösen et al. 2004; described in
Section 1.5.3). The areas differed significantly between different wall types (p<0.001;
LMM), except between types C and D. The median areas were 9% in A-type (n=12),
20.5% in B-type (n=12), 39% in C-type (n=33), and 40% in D-type (n=9) walls (I). As the
degenerated and decellularized walls (types C and D (Frösen et al., 2004); found more
often in ruptured IAs) showed larger TCC-positive areas than the proliferative B-type and
the quiescent, endothelialized A-type IA walls (found more often in unruptured IAs),
complement activation seemed to be associated with wall degeneration. Furthermore, as
complement activation was present also in all unruptured IAs, and as some IAs lacked
inflammatory cell infiltrations (Crompton, 1966; Frösen et al., 2004), complement
activation seemed to precede the inflammatory cell infiltration into the IA wall.
1.1.2 Association with macrophage and T-cell infiltration (I)
Complement activation is chemotactic for inflammatory cells. Complement activation
against foreign surfaces, e.g. those of microbes, is usually associated with an apparent
inflammatory cell infiltration. However, the lack of a correlation between complement
activation (TCC deposition) and inflammatory cells other than CD3+ T-cells (p=0.047)
and CD163+ macrophages (p=0.037) suggested an absence of an infectious focus (I).
The alternatively activated CD163+ macrophages are more likely linked to the
dampening of the inflammatory response and resolution of inflammation than to an acute
inflammatory reaction associated with direct killing of pathogens (Moestrup and Moller,
2004). CD163 is a macrophage scavenger receptor that recognizes, for instance, cell-free
hemoglobin (Fabriek et al., 2005). The IA wall has been reported to show occasional
staining for hemosiderin (Schlote and Gaus, 1994; Rajesh et al., 2004; Holling et al.,
2009) as well as for intact erythrocytes (Nyström, 1963; Scanarini et al., 1978a; Kataoka
et al., 1999), indicating clinically silent intramural bleeding. Aged erythrocytes are known
to activate complement (Peterson et al., 1989). Free iron from lysed erythrocytes causes
oxidative stress, leading to oxidative modification of surrounding particles, e.g. of LDL,
also shown to be present in IA walls (II). The oxidatively modified lipids and proteins are
capable of binding immunoglobulins, acute phase proteins, and C1q (II).
In addition to the possible hemoglobin-mediated link between complement
activation and the presence of CD163+ macrophages, other factors might also be
responsible for both complement activation and recruitment of CD163+ cells.
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T-cells are the key players of acquired immunity. Complement activation seems to
favor a regulatory T-cell response, as complement anaphylatoxins promote IL-4, -5, and -
10 production and suppress IL-12 production from leukocytes. Also cross-linking of
CD46 strongly induces development of IL-10-producing regulatory T-cells, and cross-
linking of CD59 enhances T-cell proliferation and IL-2 -production (see also Figure 6)
(Kemper and Atkinson, 2007).
The T-cell profile in human IAs has not been confirmed to date. However, the lack
of IL-10 (Jayaraman et al., 2008) in ruptured IAs and the presence of TNF-  (Jayaraman
et al., 2005) hint at the dominance of the Th1 direction or a cytotoxic T-cell response. At a
transcriptional level, the receptors for IFN- , produced by Th1-cells, Tc-cells, and activated
macrophages, are upregulated in IA walls (Krischek et al., 2008; Shi et al., 2009). In
atherosclerosis, the Th1-type response has been found to dominate (Hansson and Libby,
2006). The discrepancy between the theoretical direction of T-cells in a regulatory rather
than an effector direction and the suggestion of Th1-typed response in practice could be
explained by the complicated mechanisms that regulate inflammatory reactions in vivo.
1.1.3 Endothelial dysfunction may potentiate complement activation and
accumulation in the aneurysm wall (I, II)
De-endothelialization occurs during IA progression and has been seen in both human and
experimental IAs (Crompton, 1966; Kataoka et al., 1999; Frösen et al., 2004; Jamous et
al., 2007). In experimental IAs, endothelial dysfunction has been the earliest change in IA
progression (Jamous et al., 2007). Heavier C5b-9 accumulations were observed in de-
endothelialized IAs, and the relative TCC-positive area correlated significantly with de-
endothelialization (p<0.001; Mann-Whitney U test) (I). Also, a gradually decreasing
staining for IgG and IgM in the lumen-to-adventitia direction, accumulation of IgG and
IgM in the ECM, and accumulation of neutral lipids in the outer part of the wall were
noted. These indicate the possibility of an increased flow of plasma proteins to the IA wall
(II). No IgG and only small amounts of IgM have been detected in the walls of normal
basilar arteries (Chyatte et al., 1999). The normal centrifugal mass transport of micro- and
macromolecules through the vascular wall due to hemodynamic forces can become
disturbed in pathological conditions (Michel et al., 2007). Thus, several plasma factors,
including complement components, are hypothesized to leak and accumulate in the IA
wall because of endothelial dysfunction.
Under normal circumstances, molecules pass through the vascular wall. Vascular
stress may disturb these normal clearance mechanisms. Because of anatomical and
physiological abnormalities, the IA wall suffers from chemical and mechanical stresses.
The complement system helps in the clearance of altered host structures and particles by
V Results and discussion
66
opsonizing them. Thus, complement accumulation may indicate disturbed tissue
homeostasis and emergence of altered structures that need clearance.
1.1.4 Relationship between complement activation and cell death (I, II)
Important structural and functional components of the IA wall are SMCs, which disappear
from the IA wall upon its degeneration. The finding of a decreased number of nuclei in the
TCC-positive layers in the outer IA walls indicates a major cell loss in these regions (I). A
probable association between TCC activation and cell loss was also seen within B-typed
and C-typed walls, both of which are thick, but in which the C-type wall is decellularized.
The relative TCC-positive area was found to be almost twice as large in C-type (39%)
than in B-type (20.5%) IA walls (I).
An increase in apoptotic cell death in IAs (Hara et al., 1998; Guo et al., 2007) and
its relation to IA rupture (Sakaki et al., 1997; Frösen et al., 2004; Pentimalli et al., 2004)
have been described. Also, gene expression for downstream regulators of apoptotic
pathway, caspases 1 and 3, is upregulated in IAs (Guo et al., 2007; Shi et al., 2009). As
complement can kill cells by direct lysis and by apoptosis (Cole and Morgan, 2003;
Bohana-Kashtan et al., 2004), double stainings for TUNEL and MAC were performed.
TUNEL+ cells were found in 54% (12/22) of unruptured and 77% (24/31) of ruptured IA
walls. The proportion of TUNEL+ cells of total cell count was slightly more in ruptured
(median 26%, range 0-89%) than in unruptured (median 11%, range 0-65%) samples
(p=0.052). The presence of apoptosis was verified in electron microscopy (I). Although
TUNEL+ cells colocalized with MAC-positive areas in some ruptured samples (4/7; and in
0/7 unruptured samples) and complement depositions were found adjacent to the TUNEL+
nuclei in 5/14 samples at larger magnification, no double-positive cells were detected. In
addition, the statistically weak correlation between TUNEL+ cells and complement
activation suggested that apoptosis was not the major mechanism behind complement
activation and cell loss in the IA wall. Although a massive attack against SMCs by the
MAC appears an unlikely explanation for the loss of cells in the IA wall, in one of the
series, we managed to detect C5b-9-positive SMCs in one unruptured IA and a few C5b-9-
positive cells in 4/10 other unruptured IAs (II).
Occasional findings of MAC near TUNEL+ cells could be indicative of a role of
complement in the clearance of cellular debris in the IA wall. It is well known that
complement can become activated as a clearance mechanism to remove cells (Cole and
Morgan, 2003; Bohana-Kashtan et al., 2004). In fact, immunoelectron microscopy
revealed that structures in the area of MAC accumulation probably represent cellular
debris. MAC was also found on remnants of cell membranes. In light microscopy, the
majority of MAC localized to ECM (I). A recent study on a series of perioperatively
resected ruptured IAs revealed necrotic cell death in a remarkably large proportion of IA
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samples (Holling et al., 2009). This supports also the finding of necrotic cells in electron
microscopy (I). The rarity of colocalization of MAC and TUNEL+ cells suggests that
complement-mediated cell death and apoptosis both have their own distinct roles in cell
loss. However, it should be noted that although TUNEL assay is widely used to detect
apoptotic cell death, the assay also detects cells that have DNA fragmentation for other
reasons, including proliferation, necrotic cell death, or tissue preparation (e.g.
cryosectioning).
1.1.5 Complement activation and other clinical and histological parameters
In general, TCC activation was not associated with other clinical (patient age, sex,
multiplicity of IAs, prior SAHs, Fisher’s grade, or IA dimensions) or histological
parameters (presence of remnants of IEL, organizing thrombus, atherosclerotic
calcifications, pads of intimal hyperplasia, or cell proliferation; amounts of CD11b+ or
CD68+ macrophages, CD45+ leukocyte infiltrations or proportion of TUNEL+ cells)
(p>0.05; Mann-Whitney U, Kruskal-Wallis, and Spearman-Rank correlation tests). The
lack of these associations indicates that complement activation is more specifically related
to cell loss, as discussed above.
1.2 Complement activation pathways and potential complement
activators
Both the classical and alternative pathway components stained positive in the IA walls, the
maximum positive staining being in the outer part of the wall in the same area as C5b-9.
Many of the potential complement activators studied were distributed in wide areas in the
IA wall. The neutral lipids were an exception, as they colocalized with C5b-9 (Figure 9).
1.2.1 Activation via the classical pathway and recruitment of alternative
pathway amplification (II)
The presence of C1q together with C4b/iC4b and C5b-9 clearly indicates that the classical
pathway of complement has become activated in IA walls. Properdin, a specific marker
for alternative pathway activation, was seen only weakly in IA walls. Complement
C3b/iC3b deposits were also observed in the same areas and usually in greater abundance
than C4b/iC4b, whereas the area positive for C3d was more restricted. The presence of
C4b/iC4b in the same areas as C3b/iC3b and C3d may indicate that classical pathway
activation has recruited alternative pathway amplification in the IA wall. The deposition of
C3d, a covalently bound long-lived breakdown product of C3b, suggests that a more
prolonged inflammation and complement accumulation in the IA wall has occurred (Davis
et al., 1984; Nakagawa et al., 2000).
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The classical pathway has been suggested to be active also in atherosclerotic
plaques (Yasojima et al., 2001a; Oksjoki et al., 2003a). In AAAs, the presence of
increased amounts of several IgG subtypes together with C3 degradation products has
been suggested to indicate complement activation by the classical pathway (Capella et al.,
1996). Interestingly, many chronic inflammatory diseases, i.e. rheumatoid arthritis,
atherosclerosis, and membranous nephropathy, show signs of parallel involvement of the
classical and the alternative pathways (Cunningham and Quigg, 2005; Theroux and
Martel, 2006; Okroj et al., 2007). The alternative pathway may become recruited in the
inflamed tissue following persistent classical pathway activation due to the action of the
C3/C5 convertases and alternative pathway amplification (Sim and Tsiftsoglou, 2004;
Sjöberg et al., 2009). However, in IAs the virtual lack of properdin underlines the role of
classical pathway activation, and thereby, the potential importance of the classical
pathway activators in IA pathobiology.
1.2.2 Several known complement activators are present in the aneurysm
wall (II)
IgG as well as IgM were seen in the IA wall, mostly bound to the ECM. IgG was detected
in 61/90 (68%) and IgM in 8/10 IAs. Of the IgG-positive and -negative samples, 62%
(38/61) and 55% (16/29) were ruptured, respectively (p=0.520, 2 test). This finding is
consistent with previous results of immunoglobulin accumulation in abnormal vascular
tissues. Abdominal aortic aneurysms show strongly increased amounts of IgG together
with complement C3d (Capella et al., 1996). IgG was located diffusely in the ECM in a
majority (93%; 57/61) of the samples, whereas IgM stained more in a patch-like manner.
IgM and antigen-bound IgG subclasses IgG1 and IgG3 are potent complement
classical pathway activators. The majority of IgMs are naturally occurring antibodies
(NAbs) which have been proposed to activate the classical pathway in, for example,
myocardial infarction (Zhang et al., 2006). Oxidized epitopes, present also in cells and in
the ECM of IA walls, have recently been found to be the main targets for naturally
occurring antibodies (Chou et al., 2009). NAbs have a low affinity to multiple ‘nonself’
and ‘self’ antigens, e.g. negatively charged phospholipids and other antigens exposed
during apoptosis (Ochsenbein and Zinkernagel, 2000; Fleming, 2006). In addition to IgM,
also IgG3 and IgA isotypes occur among NAbs (Ochsenbein and Zinkernagel, 2000;
Fleming, 2006).
As hypothesized, immunoglobulins may leak and accumulate in the IA wall
because of endothelial dysfunction. Thus, any antibodies with natural or acquired
specificity for structures in the ECM would be expected to become deposited in the IA
wall. Novel antigen exposure could occur via pressure-induced damage, membrane
damage, and/or proteolysis of components in the ECM. Immunoglobulins have been
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detected earlier in unruptured IA walls in similar proportions as those seen here in both
unruptured and ruptured IAs (II), but not in basilar artery samples used as controls
(Chyatte et al., 1999). In atherosclerotic coronary arteries, IgM has been shown to
accumulate and colocalize with the classical pathway activation products C4b/iC4b in the
superficial intima (Oksjoki et al., 2007).
In normal cerebral arteries, lipids accumulate subendothelially with aging, and IEL
seems to function as a barrier limiting lipid accumulation within the IEL and intima
(Zugibe and Brown, 1961). In IAs, accumulation of neutral triglycerides and lipids was
detected in the same areas where C5b-9 was deposited. In an experimental setting, C5b-9
has been found to colocalize with extracellular lipids upon progressive lipid accumulation
in rabbit atherosclerotic aortas (Seifert et al., 1989). Native and oxidized lipids accumulate
in stressed vascular walls, and oxidized lipids may activate the classical pathway in vivo
through C1q in the presence of CRP (Frösen, 2006; Biró et al., 2007).
In IAs, the ECM stained positively in all samples (10/10) for the main LDL protein
ApoB-100 and oxLDLs. The positive staining for cells was seen with ApoB-100,
minimally modified LDL, and hydroxynonenal in 6/10, 8/10, and 10/10 samples,
respectively. OxLDLs were detected in areas positive for CRP, similarly as seen in
atherosclerotic plaques (Chang et al., 2002; Meuwissen et al., 2006), and in experimental
ischemic myocardium (Griselli et al., 1999). The detection of oxLDL in both the ECM
and cells probably indicates a generalized imbalance in oxidative and antioxidative
potential.
Peroxidation of lipids is a common event in healthy individuals, e.g. in apoptotic
cell death. In proinflammatory diseases, it becomes accelerated. The vascular wall carries
multiple oxidative mechanisms to produce reactive oxygen species (ROS). They can
modify a wide variety of extracellular and cellular proteins and lipids (Hartvigsen et al.,
2009). The formed oxidized phospholipids as well as oxidized lipoproteins are
proinflammatory, as they are recognized by natural antibodies (Baumgarth et al., 2005),
phagocyte scavenger receptors (Goldstein et al., 1979), and innate soluble proteins like
CRP (Chang et al., 2002) and complement C1q (Torzewski et al., 1998; Meuwissen et al.,
2006). The interaction between ROS and antibodies may also increase the affinity of the
antibodies to a wider range of autoantigens, as reviewed in Dimitrov et al. (2008).
Native CRP is present widely in inflamed tissues, but has been found only in a few
healthy aortas (Reynolds and Vance, 1987; Diehl et al., 2000; Ji et al., 2006). In IAs, C1q
was mostly bound to ECM similarly as oxLDL and CRP, suggesting that classical
pathway activation through C1q in IA walls could be induced by oxLDL and/or CRP.
ECM showed also a faint double positivity for CRP and C5b-9, and CRP was found in the
band-like area of heavy C5b-9 staining in the outer IA wall. However, C1q is also capable
of interacting with several matrix proteins (Sjoberg et al., 2009).
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Surface-bound CRP itself is a potent complement classical pathway activator. In
5/10 unruptured IAs, only a few CRP-positive cells were seen and in double-stainings
with C5b-9, only occasional double-positive cells were detected. However, in one
unruptured IA, many CRP-positive mural cells without C5b-9 accumulation were
detected, which might be explained by CRP’s ability to bind complement inhibitors, e.g.
factor H, to protect the target structures from further complement activation (Jarva et al.,
1999).
1.2.3 Impaired clearance mechanisms and complement activation
Only the accumulation of neutral lipids in the outer IA wall was found to colocalize with
C5b-9, as also seen in experimental studies (Seifert et al., 1989). Based on the otherwise
lacking one-to-one colocalization of complement components and potential complement
activators, complement seems to have become activated in the IA wall in response to more
than one specific activator. As the IA wall is exposed to both mechanical hemodynamic
stresses and humoral inflammatory stresses, complement activation might be caused by
the combined effect of traditional activators plus mechanochemical stress, leading to a
disturbance in the local tissue homeostasis. Increased cellular death and associated
accumulation of cellular debris may trigger and maintain prolonged complement
activation, especially in the outer part of the IA wall. Thus, disturbances and possible
overloading in the wall clearance mechanisms may lead to the accumulation of molecules
and material in the vascular wall that would normally be transported through it (Michel et
al., 2007). Many of these molecules and exposed structures can also activate complement.
1.3 Complement regulation (III)
1.3.1 Factor H and C4bp protect the luminal part of the aneurysm wall from
complement membrane attack complex
The main complement classical pathway inhibitor C4b binding protein and the alternative
pathway inhibitor factor H were detected mostly in the ECM of the luminal parts of IA
walls, whereas C5b-9 staining remained mostly negative in these areas. The luminal part
stained also with Alcian Blue, indicating the presence of sulfated glycosaminoglycans.
C4bp interacts directly with small glycoproteins of the ECM (Happonen et al., 2009).
C4bp as well as factor H have been shown to bind to arterial proteoglycans and to
colocalize with them in atherosclerotic lesions (Oksjoki et al., 2003a; Oksjoki et al.,
2007). Factor H has been demonstrated to bind to glycosaminoglycans, thereby having a
pivotal role in discriminating between complement activators and nonactivators (Meri and
Pangburn, 1990b; 1994). The finding of factor H in similar areas with
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glycosaminoglycans, but without MAC, indicates the importance of their role in
complement inhibition in the IA wall. Thus, the distribution of glycosaminoglycans and
their modulation by as-yet-unknown factors have important roles in regulating
complement activation in the IA wall.
C4bp and some factor H were also found in the area of strong C5b-9 accumulation
in the outer part of the IA wall. As expected, protein S was seen in identical areas with
C4bp in parallel sections in all IAs (18/18; 9 unruptured and 9 ruptured IAs), although
C4bp was sometimes detected in larger areas than protein S. The staining for C4bp was
especially prominent in colocalization with C5b-9, whereas factor H deposition was less
intense, only partially overlapping with C5b-9. Similarly as in IAs, in atherosclerotic
lesions, C4bp is widely expressed luminal to C5b-9 accumulation, but without an overlap
with C5b-9 (Oksjoki et al., 2007).
The partial colocalization of C4bp with C5b-9 suggests that in IAs a stronger
inbalance is present between complement regulation and activation than in atherosclerotic
lesions. This could be due to either stronger complement activation potential because of
wider vascular wall damage or weaker regulatory activity in this region.
In the IA wall, the area positive for C5b-9 has lipid-containing particles (II), a
decreased number of viable cells, apoptotic and necrotic cell death, and marked amounts
of probable cell debris (I). C4bp has an inherent capacity to bind apoptotic cells through
interaction of protein S and phosphatidylserine of apoptotic blebs (Blom et al., 2004). As
the area of heavy C4bp and C5b-9 accumulation at the outer part of the IA wall presents
only a few nuclei, the local synthesis of such amounts of C4bp only by cells in the arterial
wall seems unlikely (Yasojima et al., 2001a). Rather, C4bp is suggested to accumulate in
this area because of passive diffusion or physiological mass transport through the IA wall
(Michel et al., 2007). Why factor H did not represent similar heavy accumulation as the
C4bp, but rather a scarcer distribution, could be explained by differences in the affinity of
factor H and C4bp for the extracellular matrix components. Nevertheless, the lack of
factor H from this region may be the key factor for activation of alternative and terminal
pathways to occur.
1.3.2 CFH Y402H is not associated with intracranial aneurysms or
aneurysm rupture
The factor H polymorphic variant Y402H has been strongly associated with age-related
macular degeneration, a disease characterized by impaired eye pigment and debris
clearance (Thakkinstian et al., 2006). The role of Y402H polymorphism in cardiovascular
diseases remains controversial. One study has supported an association of the 402H
variant with myocardial infarction (Kardys et al., 2006), but further studies have failed to
confirm this finding (Zee et al., 2006; Nicaud et al., 2007; Stark et al., 2007). The factor H
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variant with histidine in position 402 has a reduced affinity for CRP (Laine et al., 2007;
Sjoberg et al., 2007). CRP is an acute-phase reactant associated with tissue damage and
inflammation, also in IA walls (II). Thus, we were interested in investigating Y402
polymorphism in patients with IAs.
However, no significant difference was seen in Y402H distribution between IA
patients and healthy controls (97 IA patients and 100 individuals representing the normal
Finnish population). Of the IA patients, 36/97 (37%) had the TT genotype, 53/97 (55%)
the heterozygous CT genotype, and 8/97 (8%) the most strongly AMD-associated CC
genotype. Of the aneurysm patients with TT, CT, and CC genotypes, 26/36 (72%), 35/53
(66%), and 3/8 (38%) had had a ruptured IA (aSAH), the distribution differing
nonsignificantly from the IA patients carrying only unruptured IAs (p=0.188; Table 3).
The CFH genotype did not correlate with recorded hypertension (p=0.101; 2 test), gender
(p=0.777, 2 test), IA diameter (p>0.173; Mann-Whitney U -test), or multiplicity of IAs
(p=0.197, 2 test). The genotypes of controls did not differ significantly from those of IA
patients: TT=41/100 (41%), CT=42/100 (42%), CC=17/100 (17%) (p=0.088; 2 test).
Although the latter comparison was based on a relatively small series, the 402H variant
(CC genotype) does not appear to have a role in IAs in general or in IA pathobiology and
rupture.
1.3.3 Protectin limits C5b-9 formation in the aneurysm wall
Protectin is a membrane-bound GPI-anchored complement regulator that inhibits the
formation of MAC. Protectin stained positive in all 44 (24 unruptured and 20 ruptured)
studied IAs. In general, the staining seen was the reverse of that of the C5b-9 complex; the
areas of intensive staining for protectin were virtually negative for C5b-9. Only faint or no
staining for protectin was observed on the matrix in the areas of strong positive staining
for C5b-9 in the outer band-like part of the IA wall. In the areas of fainter positive staining
for protectin, both C5b-9 -positive and -negative cells and C5b-9 on the matrix
surrounding the cells were seen depending on the sample. The staining was located mainly
on cell membranes, but some protectin staining was also present diffusely in the ECM.
In general, SMCs are protected against complement attack by expressing protectin,
but loss of protectin expression may occur in, for instance, myocardial infarction (Väkevä
et al., 1992). Cultured rat aortic SMCs are sensitive to loss of expression of protectin
when grown overconfluently or for prolonged periods. Thereby, the cells become sensitive
to complement attack (Capey et al., 2007). In addition, cultured porcine aortic SMCs have
been found to be extremely sensitive to complement-mediated lysis due to a low level of
expression of protectin (Capey and van den Berg, 2005). Whilst ischemic cells lose
protectin (Väkevä et al., 1992), the possible role of hypoxia in the IA wall pathobiology
remains hypothetical (Inci and Spetzler, 2000). Also the presence of macrophages in the
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IA wall (Kosierkiewicz et al., 1994; Kataoka et al., 1999; Frösen et al., 2004) may
contribute to the loss of protectin, as the majority (95%) of macrophages in atherosclerotic
lesions have been found to express GPI-specific phospholipase D, which is capable of
hydrolyzing the GPI anchor of protectin (O'Brien et al., 1999).
The areas of strongest C5b-9 accumulation were mostly in areas lacking protectin
and with only a few cells, underlining the importance of cell-mediated complement
inhibition in IAs. However, whether the lack of protectin is a cause or consequence of the
cell loss in the same area, needs to be elucidated. Either could lead to increased C5b-9
formation.
In some IA walls, the staining for protectin partially overlapped with that of C5b-9
in areas between the strongest protectin expression and the strongest C5b-9 accumulation.
A similar phenomenon has also been seen in atherosclerotic lesions (Seifert et al., 1992).
This may indicate an imbalance of complement inhibition and activation in the IA tissue.
If the changes in the IA wall are considered a continuous degenerative process ultimately
leading to critical thinning and rupture of the IA wall, this area of partially decreased
inhibitory capacity of complement activation might represent a transitional zone in the
process. Protectin has a role in preventing inflammation related to tissue debris clearance,
as indicated by studies with atherosclerosis-prone ApoE-/- mice, in which protectin-
deficient mice showed signs of accelerated atherosclerosis (Wu et al., 2009). In Study I,
the areas of intensive C5b-9 accumulation also showed lipid accumulation as well as
cellular debris. Thus, protectin may play a critical role in the IA wall homeostasis by
preventing MAC attack.
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2 Possible role of complement activation in
intracranial aneurysms
Figure 10. Schematic representation of a possible role of complement activation in the
induction of intracranial aneurysm wall inflammation and degeneration. The shear stress
from blood flow leads to endothelial dysfunction, allowing increased plasma material to diffuse into
the vascular/aneurysmal wall. The lipids are recognized by C-reactive protein (CRP), leading to
complement activation, formation of anaphylatoxins, and chemotaxis for inflammatory cells. These
will affect IA wall remodeling and result in formation of proinflammatory epitopes and cell death.
The subsequent loss of complement inhibitors and associated cell death at the outer part of the
wall enables full complement activation and C5b-9 formation, further enhancing cell death. The
luminal part of the IA wall is protected from complement activation by extracellular matrix and
glycosaminoglycan (GAG)-bound complement inhibitors, C4b binding protein (C4bp) and factor H
(fH), as well as protectin, expressed by smooth muscle cells. Immunoglobulins IgG and IgM,
capable of activating complement, accumulate in the IA wall because of endothelial dysfunction.
As C4bp binds apoptotic cells, it may accumulate in the outer part of the IA wall together with
C5b-9.
IA formation is characterized by the breakdown and loss of IEL (Crompton, 1966;
Stehbens, 1989). In atherosclerotic extracranial arteries, IEL seems to function as a barrier
that restricts lipid accumulation and associated complement activation in the intima
(Ostergaard and Hog, 1985; Oksjoki et al., 2003a; Oksjoki et al., 2007). In IAs, the
missing IEL allows the penetration of plasma proteins and lipid particles deeper into the
IA wall, seen as lipid and C5b-9 accumulations in the outer part of the IA wall (I-III).
Usually, the substances are transported through the vascular wall (Michel et al., 2007). In
V Results and discussion
75
endothelial dysfunction, however, the accumulation of lipids and protein aggregates might
exceed the capacity of normal clearance mechanisms. Furthermore, due to the function of
IEL in extracranial atherosclerotic lesions, the cells exposed to complement activation are
predominantly intimal, whereas in IAs, the exposed cells are mainly representative of
medial SMCs.
As complement activation becomes more persistent, the relative amount of
anaphylatoxins, produced during early complement activation, increases. Anaphylatoxins
themselves are chemotactic to inflammatory cells (Klos et al., 2009) and may induce both
endothelial cells (Laudes et al., 2002) and myofibroblasts (Helske et al., 2008) to produce
MCP-1, which is chemotactic to monocytic inflammatory cells. Anaphylatoxins also
induce endothelial cells to express cellular adhesion molecules (Foreman et al., 1996;
Albrecht et al., 2004; DiScipio and Schraufstatter, 2007) that aid the inflammatory cells to
migrate to the IA wall. Among inflammatory cells, anaphylatoxins can also attract
neutrophils. They are short-lived and may after their death, even within hours, release
hydrolytic enzymes, proteases, and phospholipases with a tissue-destructive effect.
However, probably at this point, the SMCs are still viable enough to express protectin
(Meri et al., 1991; Seifert et al., 1992) and DAF (Seifert and Hansson, 1989b) to inhibit
terminal pathway complement activation and MAC formation.
Inflammatory cells secrete several proinflammatory cytokines and growth factors
that probably induce the histological changes (see Figures 3 and 6), e.g. myointimal
hyperplasia and fibrosis, observed in the IA wall. As inflammatory cells express several
complement receptors (Morgan and Gasque, 1997), the inflammatory cell responses may
be in part be induced by anaphylatoxins and other complement components. The
inflammatory cells may also enhance the inflammatory response themselves by expressing
MCP-1 and synthesizing complement components (Andrews et al., 1995; Morgan and
Gasque, 1997). Migrating monocytes and macrophages also phagocytose the PMNs that
have come to the end of their mission.
As IA wall and associated myointimal hyperplasia proceed, the SMCs change their
phenotype from the contractile to the synthetic type (Nakajima et al., 2000). They increase
the synthesis of matrix (collagens), indicated by the expression of prolyl-4-hydroxylase
(Frösen et al., 2004). In fact, complement activation may also be responsible for
myointimal hyperplasia (Bohana-Kashtan et al., 2004; Shagdarsuren et al., 2008). The
SMCs within the areas of myointimal hyperplasia are probably responsible for the
synthesis of glycosaminoglycans seen in the luminal parts of IA walls (III). The arterial
glycosaminoglycans bind the soluble complement inhibitors C4bp and factor H, which
protect from complement activation in the luminal parts of IAs, similarly as observed in
atherosclerotic lesions (Oksjoki et al., 2003a; Oksjoki et al., 2007). For the most part,
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C4bp and factor H originate from the circulation, although some local synthesis of
complement components may also occur.
At this later stage, the IA wall has probably accumulated many potential
complement activators, including immunoglobulins, CRP, and lipids from the circulation
(II). In addition, proteins and lipids (II) oxidatively modified by the action of ROS and
RNS by macrophages, the main targets of NAbs, can deposit in the IA walls (Chou et al.,
2009). All of these factors can activate the classical complement pathway (II). This leads
to alternative pathway activation (II) and ultimately to MAC formation (I-III) in areas with
limited complement inhibitory capacity (III). This is probably a key factor maintaining
inflammation in the IA wall. Ongoing inflammation always increases the probability of
formation of PAMPs and epitopes recognized specifically by antibodies formed in
response to a prior exposure to an antigen (Chou et al., 2008). Ongoing inflammation and
complement activation may predispose to the development of an acquired immune
response against a newly formed epitope (Carroll, 2004b; Weyand et al., 2008).
The IA wall is supplied by oxygen, probably through direct diffusion from the
luminal side, and from vasa vasori (Takaba et al., 1998) on the adventitial side. As the IA
wall grows thicker, the blood supply to the wall by vasa vasori becomes even more
important. An experimental occlusion of the vasa vasori leads to necrosis of the outer
medial layer (Stefanadis et al., 1995). Interestingly, in a small series reported by Scanarini
(Scanarini et al., 1978a), the vasa vasori of ruptured IAs often had partial occlusions of the
lumen by probable thrombotic material. The study by Stefanadis suggested that the outer
part of the wall, “the watershed area”, was most likely the first to suffer from diminished
oxygen and nutrient supply. The distension caused by blood pressure can also weaken the
microcirculation of the arterial wall and lead to further local ischemia (Marcus et al.,
1985). Ischemia can induce downregulation of complement inhibitors and promote
complement activation, as shown in autopsy studies of heart and brain infarctions (Rus et
al., 1987; Lindsberg et al., 1996; Väkevä and Meri, 1998). Cell loss may occur in the
outer part of the IA wall because of both apoptotic and necrotic cell death (I) and
accumulation of cellular debris (I). Thus, the accumulation of C5b-9 in the outer part of
the IA wall might in part be secondary to cellular death. Thereby, local hypoxia may be an
additional factor leading to cell loss (Inci and Spetzler, 2000) and associated terminal
complement activation.
The outer part of the IA wall also lacked expression of protectin (III). SMCs are
sensitive to loss of expression of protectin under stress (Capey et al., 2007) or due to
secretion of GPI-specific phospholipase D by macrophages (O'Brien et al., 1999). The loss
of protectin makes SMCs sensitive to complement-mediated lysis (Capey and van den
Berg, 2005; Capey et al., 2007). The formation of MAC has multiple consequences,
including an increased Ca++ influx and a membrane-destabilizating detergent-like effect,
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both of which can contribute to cell activation and death. Besides C4bp and factor H,
protectin is also expressed in the luminal parts of the IA wall, limiting terminal
complement activation (III). In addition, the accumulation of complement-activating
substances in the outer part of the IA wall due to impaired clearance mechanisms (Michel
et al., 2007) may amplify complement activation. This may increase the susceptibility of
SMCs to death. As C4bp binds to apoptotic cells by protein S, both of these factors are
detected in the outer part of the wall (III). NAbs may also have a function in the clearance
of apoptotic and cellular debris (Grabar, 1983; Fleming, 2006). In conclusion, complement
activation, inflammatory cell infiltration, and cellular death together can create a vicious
circle, promoting and sustaining inflammation in the IA wall.
Increased inflammation and cellular death can lead to an imbalance between
matrix degradation and synthesis. As a consequence, the IA may rupture when the luminal
pressure overcomes the tensile strength of the IA wall. In unruptured IAs, the
inflammatory degenerative mechanisms may be compensated to reach a steady state or IA
wall degeneration may progress undetectably slowly.
3 Limitations of the study
Investigating the pathobiology of IAs is inherently limited because of the unique nature of
sample materials. As IAs are heterogeneous in histology, parallel studies should be
performed with the same samples for the most comparable results. However, since the
majority of IAs are inherently small, and the size of resected samples is even smaller,
sample size restricts the number of serial sections from a single sample. In addition,
confirming the results by parallel methods is in many cases impossible because of the
limited quantity of the sample. Due to the low number of samples available, the ideal case-
control type of study, where aneurysms could be matched by, for instance, size, patient
characteristics, and/or present risk factors, is inconceivable.
As IA wall samples are surgical specimens, the IA neck left under the clip is never
investigated. Moreover, the smallest IAs are never evaluated, as the size does not allow a
sample resection. The sample resection itself causes mechanical injury that may be seen in
histology as an artifact at the cutting edge. Having normal cerebral artery as a control
tissue would answer many methodological and interpretation-related questions. However,
obtaining an adequate control tissue as a surgical specimen is ethically impossible. The
use of extracranial arteries as a control tissue is not the best option because of inherent
histological differences.
Although a case-control study allows relationships to be evaluated, it does not
provide data on the causality and timing of certain phenomena. Demonstrating causalities
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would necessitate an animal study. However, no animal model for experimental IA where
the IA degenerates and ruptures due to chronic inflammation (as in humans) is yet
available. Unfortunately, surgically created or elastase-induced saccular arterial pouch
models do not provide an environment sufficiently similar to human IAs. Hypertension-
induced experimental IAs have some potential and similarities, but are too small for
applications other than systemic pharmaceutical manipulations.
Immunohistochemistry is a great method when adequately controlled. It can
demonstrate the presence of a given molecule and its location within the tissue sample.
However the exact binding site or localization within the mesh of structural proteins,
glycoproteins, and cells cannot be analyzed. In addition, with a preceding low-grade
complement activation, whether the formed complex is a fully assembled MAC with
polymeric C9 or a terminal complex without poly-C9 cannot be assessed.
Subarachnoidal hemorrhage as a potential source of artifact
Rupture of the IA itself and the subsequent SAH may induce complement activation, and
complement activation has been found to be associated with IA rupture. Thus, the question
arises whether complement activation is a cause or a consequence of IA rupture. That
complement activation products accumulate already in unruptured IAs suggests that
complement activation might contribute to ruptures.
The following findings indicate that the complement activation seen in ruptured
IAs has already occurred prior to the rupture. First, the unruptured IAs also show
relatively heavy accumulation of C3b/iC3b and C3d, suggesting prolonged inflammation.
Second, the magnitude of C5b-9 accumulation in the IA wall is independent of the time
from rupture to sample collection, and complement activation has also been observed in
all unruptured IAs (I-III). Third, the heavier inflammatory cell infiltrations into the
ruptured IA walls occur before the rupture (Kataoka et al., 1999; Frösen et al., 2004).
Fourth, MAC and the preceding C5b-8 complex are such large protein aggregates
(molecular weight approximately one million) (Bhakdi and Tranum-Jensen, 1981) that
their diffusion into the IA wall from the cerebrospinal fluid or circulation seems unlikely.
Fifth, no difference has been seen in complement activation between samples collected
within or after 48 hours of the aneurysm rupture (Peterson et al., 1989; Park et al., 1997)
(I). Collectively, these facts indicate that complement activation is part of an inherent
process involved in IA progression, tissue weakening, and rupture.
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4 Future perspectives
Unruptured IAs may remain intact for years and most may not rupture at all (Juvela,
2002). To direct the prophylactic but invasive treatment to rupture-prone IAs, they must
first be identified. Since the presence of inflammation or other histopathological features
is related to the probability of IA rupture, the ability to image inflammation (molecular
imaging) in unruptured IAs could aid the clinical decision of IA closure and rupture-
prevention by invasive treatment methods. In addition, as targeted pharmaceutical
therapies become more feasible, the improvements may provide mechanisms to treat IAs
in order to strengthen the wall and to slow down IA wall degeneration. These would
stabilize the IA wall and support the intrinsic mechanisms to improve healing of the
aneurysmal lesion.
4.1 Imaging inflammation
The clinical appearance of IA can already to some extent be correlated with histological
changes of the IA wall (Asari and Ohmoto, 1994). However, as the inflammatory
mechanisms in IAs are delicate, the imaging should be able to reach a resolution where
differentiation of the exact phenotype of the cellular infiltration is possible.
No reports of imaging of inflammation in human IAs have thus far been published.
However, DeLeo et al., (2009) managed to image bacterial lipopolysaccahride-induced
inflammation in an elastase-induced rabbit experimental IA model. They were able to
detect macrophages and neutrophils in the IA wall using a myeloperoxidase-specific
magnetic resonance contrast agent that has previously been used for the visualization of
myocardial I/R injury in mice (Nahrendorf et al., 2008) and atherosclerotic plaques in
rabbits (Ronald et al., 2006). Imaging of vascular inflammation has mainly been studied in
humans in atherosclerotic plaques and vasculitis. Radiolabeled 18-F-fluorodeoxyglucose
recognizes metabolically active macrophages and distributes the vulnerable and stable
plaques (Rudd et al., 2002) in positron emission tomography. The signal intensity
correlates with the density of activated CD68-positive macrophages (Tawakol et al., 2006)
in carotid plaques and AAAs (Reeps et al., 2008). The macrophage phagocytic activity
can be detected and verified by ultrasmall superparamagnetic iron oxide particles
(USPIOs) and imaged with T2-weighted magnetic resonance sequences for human carotid
plaques (Trivedi et al., 2004; Tang et al., 2009). Radiolabeled Annexin V detects
phosphatidylserine on apoptotic cells and has been successfully used to image the extent
of apoptosis in experimental aortic atherosclerotic plaques in rabbits (Kolodgie et al.,
2003) as well as in human carotid arteries (Kietselaer et al., 2004) in single photon
emission tomography. As the imaging is strongly dependent on the technology,
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advancements in imaging technology and utilization of new technologies in clinical use,
e.g. MRI with higher Teslas, will improve imaging possibilities in the future.
4.2 Improvements in treatment methods
The only IA treatment methods currently available are clipping and endovascular therapy
with coils or other embolization materials. However, these treatment methods are invasive
and somewhat risky (Molyneux et al., 2002). For patients in need of treatment of high-risk
unruptured IAs or IAs, which have already ruptured, improvements in coil technology,
e.g. coated coils, would enable more effective and permanent treatment results (Lanzino et
al., 2005). To date, coils releasing different growth factors have been tested in animal
models with varying results. The local release of bFGF induces proliferation in the wall in
the rat common carotid artery (Matsumoto et al., 2003). bFGF also causes fibrosis and
obliteration of rabbit venous-pouch and elastase-induced aneurysms (Hong et al., 2001;
Tsumoto et al., 2007). The local release of VEGF enhances vascular wall thickness,
endothelium formation, cell infiltration, lumen reduction, and fibrotization of ligated
common carotid arteries in rats (Abrahams et al., 2001; Ohyama et al., 2004). TGF- , by
contrast, has not shown any improvement in long-term occlusion of rabbit elastase-
induced aneurysms (de Gast et al., 2001) or in a canine model (Ribourtout et al., 2003).
However, it should be noted that although the surgically created aneurysm models
commonly used in testing of different embolization materials may resemble human IAs in
structure, the inflammatory milieu might differ. Also, as many human IAs are extensively
decellularized, the basis for growth factor-aided occlusion of aneurysm sacks differs from
animal models. Thus, the efficiency of such treatments warrants further investigations.
4.3 Systemic pharmacological therapy
Since inflammation can be restricted by several pharmaceuticals, an intriguing idea is to
diminish progressive IA wall degeneration and transform it into a steady-state condition
by pharmaceutical therapy. This may prevent IA rupture. Thus far, only a few
experimental animal studies of the effect of systemic pharmaceutical treatment on the
incidence and progression of IAs have been performed.
Aoki et al. (2008c; 2009a) have employed an experimental IA model in the rat.
They showed that statins (simvastatin and pitavastatin) and HMG-CoA (3-hydroxy-3-
methyl-glutaryl-coenzyme A) reductase inhibitors prevented IA progression (growth).
MCP-1, VCAM-1, IL-1 , iNOS, and MMP-9 expressions were reduced through inhibition
of NF B activation by pitavastatin. On the other hand, doxycycline, a nonspecific MMP
inhibitor, did not affect the rate of experimental IA formation in rats (Kaufmann et al.,
2006). Edavarone, a synthetic free-radical scavenger, inhibited experimental IA formation
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and decreased MCP-1, VCAM-1, and MMP-2 expression (Aoki et al., 2009c). Nifedipine,
a calcium antagonist, inhibited DNA binding of NF B, leading to a reduced size and
thickened media of experimental IAs. It also prevented the progression of IA wall
degeneration and enlargement of pre-existing IAs. Moreover, the expression of MCP-1
and MMP-2 was decreased (Aoki et al., 2008b).
In addition to pharmaceutical treatment options, one could decrease chemotactic
and proinflammatory signaling to prevent leukocyte infiltration. However, none of the
therapies has prevented IA formation in general. As IA wall degeneration and the role of
inflammation in the process are complicated, many possible treatment targets exist.
Although the biology of human IA progression might be more complicated than the
progression of experimental IAs, the results to date are promising and warrant further
attempts to refine anti-inflammatory treatments.
Anti-complement therapy
As activation of the complement system has harmful effects in many diseases,
strategies for systemic complement inhibition have been investigated widely in animal
models (D'Ambrosio et al., 2001; Acosta et al., 2004; Arumugam et al., 2009).
Administration of C1-INH has yielded promising results in neuroprotection, whereas
effects with soluble CR1 have been modest. The impact of specific antibodies against
different complement components has also been investigated in rodents and humans (Fitch
et al., 1999). However, biological therapies are fairly expensive and likely would not offer
a cost-effective option for long-term treatment. Moreover, since the complement system is
an important defense mechanism against microbes, long-term complement depletion could
lead to an increased risk of infections. However, as complement activation in IAs seems to
be a local process, local administration of a complement inhibitory agent would probably
be beneficial. Nevertheless, since complement might also have a role in the remodeling
response, complement inhibitors cannot be considered a treatment option until the
postulated positive effects of complement inhibition on IA degeneration have been
carefully verified in experimental models.
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VI SUMMARY AND CONCLUSIONS
Intracranial artery aneurysms (IAs) are estimated to be present in 2.3% of the population.
A rupture of an IA causes subarachnoid hemorrhage, with up to 50% mortality. The
annual low rupture risk of an IA indicates that most IAs never rupture. As IAs susceptible
to rupture cannot be identified, unruptured IAs are also treated in order to decrease the risk
of rupture. The current treatment options are invasive and somewhat risky.
The ultimate mechanisms behind the structural weakening and rupture of IA are
unknown. The classical IA risk factors of smoking, hypertension, age, female gender, and
alcohol abuse only partly explain the IA pathobiology. Inflammatory cell infiltrations have
been found in IAs, indicating the role of inflammation in IA wall degeneration and
rupture.
As the complement system is an important part of innate immunity, it may have a
pivotal role in mediating the inflammatory reaction in the IA wall. Complement
components have previously been shown in IA walls. In this study, the presence of
complement activation in unruptured and ruptured IAs, complement activation
mechanisms, and regulation of complement activation were analyzed. The association of
complement activation with other histological and clinical parameters was also evaluated.
Terminal pathway complement activation was found universally in all IAs, both
unruptured and ruptured ones. This indicates a role for complement activation already at
an early phase of IA progression. Terminal complement activation was observed in larger
areas in more degenerated IA walls and in ruptured IAs. This suggests a critical role for
complement activation in IA wall degeneration and rupture.
The terminal complement complex was localized especially in the outer part of the
wall in areas with cellular debris due to apoptotic and necrotic cell death. Thus,
complement activation probably has a role in the induction of cellular death.
The complement system was observed to become activated by the classical
pathway and to recruit alternative pathway amplification. This indicates the presence of
specific complement activators in IA walls. Of the potential complement activators,
immunoglobulins G and M, C-reactive protein (CRP), and oxidatively modified lipids
were present in wide areas of the IA wall. This suggests that multiple activators contribute
to complement activation. The occurrence and accumulation of activators could be due to
endothelial dysfunction and impaired clearance mechanisms. The finding of lipids
colocalizing with the terminal complement complex and CRP implicates their
involvement in terminal complement activation, possibly due to oxidative modification.
The luminal part of the IA wall was protected from terminal complement
activation by C4b binding protein and factor H, probably bound to arterial
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glycosaminoglycans. Protectin (CD59), expressed by mural cells, has an important
function in preventing the membrane attack complex (MAC) attack. The outer part of the
IA wall lacked protectin, primary or secondary to cell death, allowing terminal pathway
complement activation and MAC assembly. The outer part of the wall also lacked factor
H, probably due to lack of factor H binding glycoproteins or glycosaminoglycans. Instead,
the C4b binding protein, which binds to apoptotic cells through the anticoagulant protein
S, was present.
Complement activation was associated with infiltrations of CD163-positive
macrophages and T-lymphocytes, indicating a probable interaction of complement with
these cells. The factor H single-nucleotide polymorphism Y402H was associated with
neither the presence of IAs nor IA rupture, suggesting that it does not have a significant
role in predisposition to IA wall pathobiology.
Our findings indicate that chronic inflammation is present in IA walls prior to IA
rupture, in a manner comparable with other chronic inflammatory diseases. The
accumulation of complement-activating molecules and material in the IA wall might be
due to disturbances and possible overloading in wall clearance mechanisms. Since
complement has an important role as a proinflammatory mediator when fully activated, it
is strictly regulated in viable tissues by soluble and membrane-bound complement
inhibitors.
Combining data from experimental IA studies in animals and studies of human IAs
reveals that IAs seem to form and grow in response to hemodynamic stress and a
proinflammatory milieu that recruits macrophages and other inflammatory cells. An
underlying condition would be endothelial dysfunction. Based on the presence of
complement activation in IAs, the activated complement system may actually mediate
these reactions. The complement system may also have a more general role in IA wall
remodeling. The modulation of IA wall structures by inflammatory cells may lead to the
formation of immunogenes, which in turn can trigger complement-mediated inflammation.
An IA wall will rupture when the intraluminal pressure overcomes the wall tensile
strength, a result of a degenerative net effect of cell death and decreased matrix turnover.
This could be due to the insufficient compensatory mechanisms favored by inflammation.
Among unruptured IAs, it is unknown whether the inflammatory degenerative
mechanisms have been totally compensated to a steady-state situation or whether the IA
wall degeneration is progressing undetectably slowly.
Complement activation may also have different functions in the IA wall at
different time-points during IA progression. This was suggested by the complement
system being differentially activated in unruptured and ruptured IAs.
Since all evidence points to a major role of inflammation, partly due to activation
of the complement system, in the degenerative processes leading to IA rupture, anti-
VI Summary and conclusions
84
inflammatory therapy could provide a tempting option for stabilizing the IA wall to
prevent IA rupture. However, the new treatment options have been tested in experimental
IAs only. Human IAs may have additional pathobiological mechanisms in IA formation,
growth, and/or rupture, and caution is therefore needed in extrapolating these findings to
human IAs. Nevertheless, advancements in (molecular) imaging and more sophisticated
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